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Abstract
Although protein based therapeutics is the fastest growing sector of the pharmaceutical industry,
production costs remain incredibly high and rapid commercialization of new protein drug
candidates are not being fully realized due to the presence of many barriers, namely the physical
and chemical instabilities of proteins. Of these degradation pathways, protein aggregation is
arguably the most common and troubling manifestation of protein instability, occurring in almost
all phases of development. Protein aggregates are usually nonnative in structure, may exhibit
reduced biological activity, and can remain soluble and/or precipitate from solution. In addition
to reducing efficacy, if administered to a patient, aggregates can cause adverse reactions, such as
immune response, sensitization, or even anaphylactic shock. Therefore, if even a small amount
of aggregates form during formulation or storage, a product can be rendered unacceptable.
Moreover, for the practical application of traditional and novel drug delivery techniques, protein
based therapeutics must be formulated at relatively high concentrations and must remain stable
for extended periods of time. The structural differences among various proteins are so
significant, that the application of a universal stabilization strategy has not yet been successful,
though the effects of common excipients are generally universal. The current approach toward
stabilizing protein drugs against aggregation is by trial-and-error testing of different
combinations of cosolutes (e.g. salts, sugars, surfactants, amino acids, etc.) using empirically
derived heuristics. While ubiquitously used, this approach is inefficient and does not always
enable the discovery of stable protein solution formulations. In response to this major problem,
we have developed and tested a new class of excipients that has the potential for wide spread
application as a universal stabilizer of protein therapeutics. When compared to other commonly
used excipients, our novel excipients offer more than an order of magnitude improvement at
suppressing the aggregation of a model protein. As a result, if used in formulations, the shelf life
of a protein drug, at room or refrigerated temperatures, may be extended from a few weeks to
several months or years. Furthermore, these excipients will likely be useful during production
and purification for improving yield and lowering downstream purification costs.
Thesis Supervisor: Bernhardt L. Trout
Title: Professor of Chemical Engineering
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1.1. Background on Protein Aggregation
Protein based therapeutics (e.g. monoclonal antibodies) have become indispensable in the
treatment of a wide variety of diseases and disorders. In comparison with small chemical drugs,
protein pharmaceuticals have high specificity and activity at relatively low concentrations, in
addition to eliciting minimal side effects [1, 2]. Moreover, recent advancements in recombinant
DNA technology have allowed for the development of potent drug candidates and new high-
throughput methodologies have allowed such products to be produced on a large scale [3]. As a
result, protein drug development has become the fastest growing sector of the pharmaceutical
industry, leading to over one hundred protein based drugs brought to market in the last decade
alone, with hundreds more in some phase of development [4].
Regardless of the rapid growth and increasing demand, production costs continue to
remain high and the commercialization of many protein drug candidates have not been fully
realized due to the presence of many barriers, namely the physical and chemical instabilities of
proteins. Of these degradation pathways, protein aggregation (the assembly of protein molecules
into multi-meric states, (see Figure 1-1)) is arguably the most common and troubling
manifestation of protein instability, occurring in almost all phases of development [5]. Protein
aggregates are usually nonnative in structure, may exhibit reduced biological activity, and can
remain soluble and/or precipitate from solution. In addition to reducing efficacy, if administered
to a patient, aggregates can cause adverse reactions, such as an immune response, sensitization,
or even anaphylactic shock [6]. Therefore, if even a small amount of aggregates form during
formulation or storage, a product can be rendered unacceptable (which can easily derail the
product development process for a biotech company). To make matters worse, for the practical
application of traditional and novel drug delivery techniques, protein based therapeutics must be
formulated at relatively high concentrations and must remain stable for extended periods of time
[7].
















Figure 1-1: An overview of protein aggregation pathways. Proteins in the native state can form native like
oligomers, fibrils, and crystals. Partially unfolded and completely unfolded proteins can form nonnative
aggregates and amyloid fibrils. All forms of the associated state are undesirable and potentially harmful.
1.2. Stabilization Methods
As mentioned above, the administration of therapeutic proteins is restricted to injections,
either intravenously or subcutaneously, because any protein taken in pill form would be digested
before it could be absorbed into the blood stream (that is unless novel and revolutionizing
delivery methods are introduced). For injections, both doctors and patients desire doses of
therapeutic proteins to be dissolved in a minimal volume of aqueous solution because the
intravenous injection of larger volumes requires a longer time in the clinic and large-volume
subcutaneous injections often cause patient discomfort at the site of injection. To minimize the
injection volume of a biopharmaceutical solution, the protein must be dissolved at a relatively
high concentration in an aqueous media. However, as mentioned above, aqueous solutions are
intrinsically unstable due to aggregation, especially at high concentrations.
One of the simplest methods for preventing or slowing aggregation (besides preparing
dilute solutions) is to freeze the solution or store it at refrigerated conditions. However, this is not
always effective and often, is not a viable option. Therefore, the most prevalent method for
combating protein aggregation, in addition to tuning buffer conditions, is to add to the solution a
low molecular weight additive (commonly referred to as a cosolute, cosolvent or excipient), such
as salts, sugars, polyols, etc., which have the propensity to deter aggregation [2, 8].
Unfortunately, due to the diversity in protein chemistry and structure, additives that work well
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for a particular protein may not work universally. Industrial researchers typically select these
excipients via a trial-and-error approach using empirically derived heuristics. Since there is no
reliable method to predict the optimal additive(s) or the best additive concentration for the
stabilization of a given protein, it is typical for a very large number of formulation experiments
to be performed, using different types and concentrations of salts, sugars, surfactants, polyols,
and other inert molecules. In addition, the interaction between common solution additives and
proteins is typically weak, thus requiring a high concentration to be effective [9].
It is often the case that this approach fails to yield a formulation with acceptable stability,
and in this case, the protein drug must be lyophilized and reconstituted later by the doctor or
patient. Aqueous formulations, however, are greatly preferred over lyophilized ones because (1)
reconstitution adds one more step to the delivery of the drug and this step can be cumbersome
and increases the potential for errors, (2) lyophilization is not without major challenges (e.g.
precipitation of buffers during freezing can lead to detrimental pH changes, proteins can undergo
conformational changes in the lyophilized state leading to degradation, slight imperfections in
temperature and pressure control can lead to undesirable product quality, etc.) and (3) cutting-
edge, highly advantageous delivery methods (e.g. delivery via slow-release implantable devices)
cannot be used with lyophilized drugs. Furthermore, even if the drug can be successfully
formulated in aqueous solution, the development of stable but higher concentration formulations
is often a goal of drug development. The higher the concentration of the biopharmaceutical, the
better the delivery methods can be. For example, if very high concentrations (100 mg/ml+) were
possible, these drugs could be packaged in implantable devices for controlled release, a
completely new and highly desirable method for delivery of biopharmaceuticals. At this point,
however, the most significant new family of biopharmaceuticals, therapeutic antibodies,
typically must be delivered intravenously. Subcutaneous injection, which requires much higher
concentrations than intravenous delivery, is much less cumbersome and is highly desired over
intravenous injections.
Therefore, due to the serious issues and complications associated with protein
aggregation and the ineffectiveness of current stabilization methodologies, there is great interest
in developing new solution additives which are very effective at deterring aggregation and are
also potent at low concentrations. However, the current understanding of the mechanisms by
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which commonly used additives (e.g. arginine hydrochloride) deter aggregation is limited and
elucidating these mechanisms of action will be of great use as well [10].
1.3. Thesis Objectives
The main objective of this thesis was to develop and test a novel class of excipients with
the aim of dramatically improving the stabilization of protein therapeutics against
aggregation. In addition to this, we also aimed to elucidate the mechanism by which arginine
(a model excipient) and our novel excipients inhibit aggregation to further improve excipient
design and biopharmaceutical stabilization.
1.4. Organization of Thesis
The remaining six chapters in this thesis gives an overview of how we began with a simple
theory developed in our group, which describes a novel class of aggregation suppressing
additives called "neutral crowder", and ended with a variety of synthesized compounds that
behave in such a manner and improve aggregation suppression by more than an order of
magnitude. Chapter 2 (Background on Solution Additives) gives a detailed overview of currently
used excipients, how additives interact with proteins, how this interaction influences stability, a
description of the Neutral Crowder theory, and our initial excipient design features for creating
"neutral crowder" compounds. Chapter 3 (Experimental Procedures) describes all procedures
used to develop, test, and analyze the novel excipients. Chapter 4 (Elucidating the Arginine
Mechanism) describes the aggregation suppression behavior of arginine, simple improvements
we discovered, and what we have elucidated about its mechanism of action (which has
characteristics similar to a "neutral crowder" compound). Chapter 5 (Novel Excipient
Development) details the different types of novel excipients we developed and their performance
at suppressing aggregation. Chapter 6 (Conclusions) gives an overview of the research conducted
and summarizes the working compounds we developed. And finally, Chapter 7 (Future Work)
describes much of the immediate work that will have to be accomplished before the newly
developed excipients can be commercialized and utilized by the pharmaceutical industry.
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2. Background on Solution Additives
2.1. Aggregation Pathway Model
The mechanisms by which commonly used additives inhibit aggregation are not quite
clear, though in a few cases, qualitative mechanistic models have been developed to describe
how a particular additive deters aggregation. For example, during aggregation, it is generally
believed that a protein molecule that is initially in the native state (N) reversibly passes through a
partially unfolded intermediate (I), which is aggregation prone, before proceeding to irreversibly
form aggregates with nonnative characteristics (An) [11]:
1
n
This mechanism is possible because a protein in its native state is not static. The secondary
structural elements of the protein continually undergo small movements in space, allowing for
the formation of partially unfolded species. Furthermore, in this model, there are two types of
additives which will deter aggregation, conformational stabilizers and association suppressors.
A conformational stabilizer is classified as any additive which shifts the folding
equilibrium from the partially unfolded state toward the native conformation. It has been
demonstrated that such additives (e.g. sucrose, glucose, polyols, etc.) are preferentially excluded
from the protein-solvent interface and thus exhibit an unfavorable interaction with the protein.
This unfavorable interaction is greater for the partially unfolded species due to a larger solvent
exposed surface area and is minimized when the protein adapts a state with minimal surface area,
such as its native state [12]. Thus, it is generally believed that such additives deter aggregation
by decreasing the number of aggregate prone species. As a consequence, conformational
stabilizers are typically added to refolding buffers (refolding being a common technique for
recovering and purifying proteins that aggregated or formed inclusion bodies during
fermentation) to enhance proper folding and are used during storage to stabilize the native state.
However, the aggregated state also exhibits a smaller solvent exposed surface area, thus high
concentrations of such additives could actually promote aggregation, often observed as a
decrease in solubility [13, 14]. Moreover, during refolding, aggregation is a competing pathway
under kinetic control (see Figure 2-1) and to avoid the irreversible loss of protein from
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aggregation, refolding is typically done at substantially high dilutions since aggregation is a
intermolecular reaction while protein folding is a unimolecular process. To refold proteins at a
reasonable concentration, an association suppressing additive, which specifically inhibits










Figure 2-1: Competing pathways during refolding. To reduce the exposure of hydrophobic residues upon
removal of the denaturant, the protein can either fold into the native state or aggregate into a multimeric
state. Which path the protein chooses will depend on solution conditions.
One such additive is the amino acid arginine [16]. It has been well documented that
arginine has very little effect on the folding equilibrium, yet it deters aggregation during
refolding and storage [17-19]. Therefore, it is assumed that arginine is an association suppressant
and not a conformational stabilizer. Based on the limited data available, researchers have
proposed different hypotheses to explain the phenomenon [9, 15, 17, 20]. In addition, researchers
have attempted to discover or develop other additives that are similar to arginine, but more
effective at hindering aggregation [21-25]. Despite all of this, the mechanism by which arginine
functions is still not well understood.
2.2. Commonly Used Excipients
The description above is a somewhat simple and generalized description of how
excipients inhibit aggregation. Most aggregation suppressing excipients can be described in such
a manner, however, some exhibit unique behavior (e.g. polyethylene glycol). Moreover,
formulation development is usually a bit more involved, taking into consideration other factors
...........
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that influence stability (e.g. pH, ionic strength, buffering components, surface adsorption,
solubility, other degradation pathways, etc.).
Determining the ideal pH is an essential first step in formulating proteins since it has a
large influence on colloidal and conformational stability, solubility, and the reaction rates of
other degradation pathways. Choosing an appropriate buffering component (i.e. one that
produces favorable stability or solubility) and determining an ideal overall ionic strength are
important as well. Moreover, almost all formulation recipes include a nonionic surfactant (e.g.
polysorbate) which inhibits surface adsorption and aggregation induced by shaking and shearing.
Furthermore, the most common excipients utilized for inhibiting aggregation are usually
conformational stabilizers (e.g. sucrose, trehalose, glycerol, mannitol, sorbitol, etc.).
Regardless of the type of excipient used, the effect folding stabilizers, association
suppressors, salts, buffering components, etc. have on solubility, conformational stability, and
other macromolecular reactions, can be described via preferential interaction theory.
2.3. Additive-Protein Preferential Interactions
Preferential interaction theory is the thermodynamic framework developed to quantify the
effect of cosolutes on protein stability. Preferential interactions, though weak in nature, will
significantly influence the solubility and stability of a protein in addition to influencing protein-
protein interactions [9, 26]. These interactions can be quantified through the use of parameters
called preferential interaction coefficients.
2.3.1. Preferential Interaction Coefficients
2.3.1.1 Cosolute-Protein Preferential Interaction Coefficient l'p3
The preferential interaction coefficient of interest, 1-'U3, is defined by the following partial
derivative,
F = - 3  , (3.2)(am2 )T, P,p3
which describes how the cosolute molality (M3 ) must change to maintain a constant cosolute
chemical potential (p3) when there is a change in protein concentration (M2), with the additional
constraints of constant temperature (T) and pressure (P) [27]. The subscripts used indicate
solution components in Scatchard notation: water (subscript 1), the protein (subscript 2), and the
cosolute (subscript 3) [28]. Alternatively, a thermodynamically equivalent definition can be
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expressed by the partial derivative relating the chemical potential of the protein to that of the
cosolute, at constant temperature, pressure, and protein molal concentration:
F /3= -(JU . (3.3)
a 3 JT,P,m2
These partial derivatives indicate that F P3 is both a measure of how the chemical potential
of the protein is perturbed by the presence of the cosolute and a measure of how the cosolute
concentration must change to maintain a constant chemical potential when protein is added to the
solution. The later description has been interpreted using a two-domain model as the difference
in the cosolute concentration between the local domain surrounding the protein and the bulk
solution [29, 30]. As shown in Figure 2-2, under such interpretations, additives with a positive
FP3 are typically described as being preferentially bound to the protein surface due to an increase
in the concentration of the cosolute in the local domain and this favorable interaction, as
indicated by Eq. (3.3), lowers the chemical potential of the protein. The opposite is true for
additives with a negative F,3, which are typically described as being preferentially excluded
from the surface of the protein.
-----. 0 0
A 0 1
Figure 2-2: A simple diagram depicting the two extremes of preferential interactions. (A) depicts the situation
in which the cosolute (grey circle) is preferentially excluded from the surface of the protein (T,< 0) and (B)
depicts the situation in which the cosolute is preferentially bound to the surface of the protein (r.> 0).
2.3.1.2 Other Preferential Interaction Coefficients
Even though values for FP3 are essential in understanding how cosolute molecules
interact with a protein, the parameter, however, cannot be measured directly because the
chemical potential of the cosolute cannot be selectively held constant. Therefore, an
approximation must be obtained. This can be accomplished by defining other preferential
interaction coefficients. The first is the isoosmolal preferential interaction coefficient, F,,, which
.......................... .. ............ 
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is defined by the partial derivative describing the change in cosolute molality (M3 ) with respect to
protein molality (m2) at constant temperature, pressure, and water chemical potential (pi):
F am (3.4)
2T,P,pui
The constraint of constant p1 can be achieved via vapor pressure equilibrium and thus the
parameter defined by Eq. (3.4) can be determined directly by VPO techniques, which will be
described later [27].
The second preferential interaction coefficient is the dialysis equilibrium preferential
interaction coefficient, FU,-3, which is assumed to be approximately equal to FP3 and is defined
by the partial derivative describing the change in cosolute molality (M3) with respect to protein
molality (M2) at constant T, pi, and p3:
8mF = 3  ~ F. (3.5)P1',/'3 am y i 2  4~/3
The constraints of constant p and p, while allowing pressure to vary are the conditions of
dialysis equilibrium, given that the protein cannot diffuse across the membrane, thus the
parameter defined by Eq. (3.5) can be determined directly by dialysis/densimetry techniques [31-
34].
2.3.1.3 Dialysis/Densimetry Technique for Determining 1
For several decades, the only established method for approximating FP3 has been through
measuring F 1,- 3 via the dialysis/densimetry technique. Other techniques for determining the
change in cosolute concentration (e.g. refractive index) upon dialysis have been utilized, but the
procedure is essentially the same. As described elsewhere, the change in mass and volume
resulting from allowing a protein solution to reach dialysis equilibrium with the solvent (here
solvent refers to the cosolute-water solution) can be attributed to a change in the mass and partial
specific volume of the protein [35, 36]. By doing so, FI,P3 can be related to the partial specific
volume at infinite dilution of the protein before (20) and after dialysis (2'0), along with the
partial specific volume of the cosolute (V3 ), the density of the solvent (ps"), and the molecular
weights of the protein (M2) and cosolute (M3):
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FF = M2 0 -02 . (3.6)M 3 1/Ps -V3)
The partial specific volume of the protein is taken at infinite dilution since this value
represents the partial specific volume with no protein-protein interactions and can be determined
by extrapolating the apparent specific volume data (#), as determined through density
measurements of the protein solution (p), to zero protein mass concentration (C2):
#; I' li02 = liM -1 37
c2-o c p C2-0 C2  1.
The partial specific volume of the cosolute at a given concentration is assumed to be the same as
that for a solution with no protein, thus it can be determined from changes in solvent density with
respect to cosolute mass fraction (z3):
V3 = --+( -z3). (3.8)
/T ,Pz 2=0
2.3.1.4 Thermodynamic Relationship between Osmolality and -
Recently, a new methodology utilizing vapor pressure osmometry has been introduced as
a means for approximating F.3 [27, 37]. The advantage of this technique over
dialysis/densimetry is that only a relatively small volume of sample is needed for the
measurements and numerous F,3 data points covering a wide range of cosolute concentrations
can be gathered in a single day. The only major drawback of this technique is that a very high
concentration of protein is required to clearly distinguish the change in water activity from the
reference solution. A vapor pressure osmometer is essentially a highly accurate dew point
hygrometer. It uses the dew point temperature of a small volume of air in equilibrium with an
aqueous solution to report the osmolality (Osm) of the solution (via the Clausius-Clapeyron
equation), which is related to the activity of the water (a,) in the solution:
Osm -min a,. (3.9)
To use such measurements to determine the preferential interaction coefficient, a
relationship must be expressed relating the parameter to the activity of water. This is done by
substituting in the relationship between chemical potential and activity into Eq. (3.3) and
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substituting in the Gibbs-Duhem relationship for one of the solutes. This produces two
alternative equations relating F P3 to the activity of water:
F, mn r1na1  (3.10)
"4 m2 a ln a3 ),, m2
F" M. (3.11)
"4 m (a ln a,/an a2 )TPm +m2 j
However, the change in the activity of the cosolute (Eq (3.10)) or the protein (Eq. (3.11)) cannot
be measured independently, thus their values must be approximated. One such method is to
assume that the change in the activity of either solute in the three component solution is
approximately the same as the change in a two component solution containing only that solute
and water. By doing so, the change in the activity of the protein and the cosolute can be
approximated from osmolality measurements via the Gibbs-Duhem relationship,
alna3 a a n a'( 2 ) _ _mn_ (2 (3.12)
M3
8lna2 ~81na'na ) - - -In a'(3), (3.13)
M2
where the superscript o(i) represents a two component solution lacking component i. By applying
the chain rule and Euler's reciprocity to Eqs. (3.10) and (3.11), along with substituting in these
approximations, the definition of osmolality (Eq. (3.9)), and a symbol to simplify the expression,
k = , (3.14)
Qm =T,P,mk' k
two alternative and equally valid approximations can be expressed relating F P3 to solution
osmolality:
F3 ~ m3 1i _ 3 (3.15)
P3 m2 Q(2
m3 2 (3) - 2)F" ~)(3.16)
3 m3h +m2 (Qxi2c -b2)
Moreover, the second approximation can be further simplified by realizing that,
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F - 2 (3.17)
3
which reduces Eq (3.16) to
H3 (3) 1p0
F P ~ + M -3 (3.18)
In the analysis presented here, both Eqs. (3.15) and (3.18) were utilized to compute the
preferential interaction coefficient and the results presented are an average of the two computed
values.
2.3.1.5 An Exact Relationship Linking F,,,, and T3
It is clear that the two techniques for approximating the preferential interaction
coefficient measure different parameters. Therefore, it is desirable to know the relationship
between the two parameters so that a comparison of the results from the two techniques can be
made. As derived elsewhere, an exact thermodynamic relationship between F P1, 3 and F 3 can be
expressed utilizing the preferential interaction coefficients F1,1 and F, 3, along with the partial
molar volume of water (V 1 ) and the cosolute (V3) [38]:
- V3F, (m2FT -m 3)-m151T(319F ' "".- " (3.19)
""'' V 3 (m2F,, -m 3) -mVi
2.3.2. Perturbation of Free Energy
For a solute to have an effect on a reaction or macromolecular process (e.g. unfolding,
precipitation, etc.), a change must occur in the interactions of that component with the entity (i.e.
the protein) undergoing the reaction. This interaction can be expressed through the change in the
chemical potential of the protein when transferred from water to the cosolute system, defined as
the standard free energy of transfer (Ap2"') and is related to the preferential interaction coefficient
as follows [39]:
Ap = f 2  d 3 = -f3 F( L 2 din -RT f ( jJ dm ~ -RTF 3  (3.20)
Eq. (3.20) reveals that for protein-cosolute systems with positive values of F,3 the
interaction between macromolecule and the cosolute causes the chemical potential of the protein
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to decrease as a result of introducing the cosolute to the protein solution. The opposite is true for
negative values of F,,3 (i.e. the interaction causes the chemical potential to increases). If during a
macromolecular process (e.g. denaturation), the interaction between a macromolecule and a
cosolute changes during the course of the reaction (in the given example of denaturation, the
macromolecule surface area changes during the course of the reaction, which influences the
interaction with cosolute molecules), the free energy of transfer will differ between the reactant
and product, which means the difference in the standard Gibbs free energy between the product
and the reactant will change as a result of adding the cosolute to the solution. This of course will
influence the reaction equilibrium, which can be expressed mathematically by the Wyman
Linkage Relation [39].
2.3.3. Wyman Linkage Function: Conformational Stability and Solubility
As described above, F P3 is a measure of how the cosolute perturbs the free energy of the
protein and such interactions will influence macromolecular interactions if the interaction differs
between the reactant (R) and product (P) states. According to the Wyman linkage relation, this
relationship can be expressed by,
aAG ralnK pP _R
y /i )=lf 3 -3 ,13 (3.21)8p3 alna3
where AG* is the standard Gibbs free energy change for the reaction and K is the equilibrium
constant. Thus, additives which have a greater affinity for the product state over the reactant
state, will shift the reaction equilibrium toward the product state (the opposite being true for
additives which have a lower affinity for the product state) [40]. Two classic macromolecular
reactions of importance here are protein folding and protein precipitation. For example, additives
which bind more strongly to the unfolded state will tend to unfold proteins. Such additives also
tend to increase solubility, thus protein binding additives both denature proteins and dissolve
precipitates because the unfolded and dissolved states allow for more binding of the additive.
It should be noted that preferential interaction coefficient measurements only indicate
how a cosolute interacts with a protein in its native state. A direct correlation between
preferential interaction measurements and solubility can be made though and is absolute because
the precipitated and dissolved states only differ by the amount of surface area exposed to the
solvent, thus the nature of the interaction with a cosolute does not differ between the two states.
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However, the physical properties of the unfolded state are significantly different from the
physical properties of the native state and therefore, the nature of the interaction with a cosolute
may differ between the two states. For example, the interaction between a cosolute and a protein
may be influenced by amino acid specific, binding site specific, electrostatic, hydrogen bonding
and/or hydrophobic interactions, which are all dependant on the conformation of the protein.
However, this is often not the case since most cosolutes interact with proteins in a nonspecific
manner (e.g. steric exclusion, surface tension perturbation, etc.), thus only the amount of surface
area exposed contributes to the difference in such interactions. As a result, a correlation between
conformational stability and preferential interaction measurements can only be generalized.
Therefore, other thermodynamic techniques which involve thermal unfolding (e.g. DSC, CD
Spec., etc.) are required to confirm how a cosolute influences conformational stability.
2.4. Association Suppression
2.4.1. Baynes-Trout Neutral Crowder Theory
The work of a prior group member, Brian Baynes, has suggested the possibility of a new
class of additives which should deter protein-protein association, thus acting on the second-order
process of protein aggregation [41]. The inspiration for this new class of excipients derives from
a theory developed in the group which describes how additives affect the rate of protein
association reactions. This idea, called "gap effect theory", demonstrates that it is possible for an
additive to exert a purely kinetic effect on protein association reactions [10]. To illustrate, a free
energy reaction coordinate diagram of the "gap effect" is shown in Figure 2-3. In the diagram,
large additives exhibiting the desired behavior (black circles) and water (grey circles) can both
solvate protein molecules (P) equally well, either when in the dissociated (P+P) or associated
(P2) state, and as a result, there is no thermodynamic effect on which state the protein chooses to
be in. However, at intermediate separation (center), there will be a separation distance where the
gap between the protein molecules excludes the large additives for steric reasons but still allows
water to solvate the gap. This results in a net preferential exclusion of the additive and a selective
free energy increase in the encounter complex (i.e. the activation energy for the association
reaction). Theoretical simulations show that this effect can greatly slow protein association
reactions. Specifically, it is possible for a relatively large additive, which does not substantially
affect the free energy of isolated protein molecules, to significantly increase the free energy
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barrier for protein association. We call such additives "neutral crowders" because in theory, they
do not affect the end states of the reaction or the free energy of unfolding, and are, hence,
"neutral" to protein stability but if they are of significant size relative to water and are present in




Figure 2-3: The gap effect. The entropically unfavorable exclusion of "neutral crowder" molecules raises the
activation energy for protein association even though the free energy of the dissociated and associated states
is not perturbed.
Figure 2-4 shows how the size and preferential interaction of an additive influences the
rate of protein aggregation, as predicted by the "gap effect theory" developed by Baynes and
Trout. The figure reveals that if a relatively large neutral crowder molecule (radius > 8 A) can be
synthesized and used as an additive to a protein solution, it has the potential to suppress protein
association rates to a significantly greater extent than any other additive developed to date. In
Figure 2-4, the relative association rate constant (ka/kao), which compares the rate in the presence
of an additive to the rate in its absence, is plotted as a function of additive radius and additive-
protein preferential interaction coefficient. The preferential interaction coefficient, Fxp (which is
the same parameter as J7, 3), is the computed preferential interaction coefficient for the interaction
with a spherical model protein (radius = 20 A). These results indicate that to suppress
association, an additive should be large and as attractive to proteins as possible because the gap
effect is seen to increase greatly with increasing additive size (e.g. an 8 A additive might be able
to suppress the rate of association by 2-3 orders of magnitude).
The Baynes and Trout gap effect theory shows that, depending on the size of the additive
and its energy of interaction with proteins relative to water, additives may accelerate, decelerate,
or have no effect on the rate of aggregation. Specifically, for design purposes, a large additive
which has an attractive interaction with proteins will slow aggregation the most. Unfortunately,
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as the size of an additive is increased, the excluded volume between the additive and protein also
increases, leading to a net increase in repulsion between the additive and protein [42]. Thus,
merely increasing the size of an additive is not an effective strategy to deter aggregation. While
larger size is desirable to emphasize the gap effect, an additive that is too large will exert a
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Figure 2-4: Association rate depression with increasing additive size, as predicted by gap effect theory
(reproduced from [101).
The key to designing a large, anti-aggregation additive will be to increase (moderately)
the additive's size, while also making additive-protein interactions more favorable. The strategy
for making interactions with protein molecules more favorable is to functionalize the additive's
surface with guanidinium groups, which are known to bind to proteins. It is logical to assume
that as the number of guanidinium groups on the surface of an additive is increased, the net
interaction energy between the additive and proteins will become more attractive. However, if
attractive forces between the new additives and proteins are too great, the additives will
destabilize the protein structure and lead to unfolding or partial unfolding. Such action is similar
to that of chaotropic denaturants such as guanidinium hydrochloride and urea. Thus, one must
seek to balance the attractive interactions due to the surface groups with repulsive forces that
result from excluded volume effects to produce an additive that acts net-neutrally with a protein.
This is the key idea behind developing neutral crowders.
...... ... .. . 
........... .
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2.4.2. Arginine: A Putative Neutral Crowder
Gap effect theory suggests that large solution additives which do not affect the free
energy of isolated protein molecules can slow down the kinetics of protein-protein association
reactions. Such molecules, called "neutral crowders," are rare because as additive size is
increased, the preferential interaction coefficient and hence protein transfer free energy falls off
in proportion to the additive radius raised to the third power, due to an excluded volume effect.
However, the aggregation suppressing behavior of arginine hydrochloride, ArgHCl, a naturally






Figure 2-5: Structure of Arginine Hydrochloride (ArgHCl).
We assume that arginine hydrochloride is a "neutral crowder" because it has been shown by us
and others that ArgHCl:
* Stabilizes proteins against aggregation but does not stabilize them against unfolding,
as demonstrated by no improvement in a protein's melting temperature upon addition
of ArgHCl to the solution [18].
* Reduces attractive protein-protein interactions as indicated by a shift from negative to
a positive osmotic second virial coefficient, B22 , values, as indicated by light
scattering experiments [43].
* Decreases the rate of association of globular proteins, as measured by surface
plasmon resonance [15].
* Decreases the rate of association of unfolded and partially unfolded intermediates
which are on the folding pathway during refolding, as measured by native protein
activity and size-exclusion chromatography [15].
All of this observed behavior is consistent with the "neutral crowder" theory, hence our
interest in fully characterizing the behavior of arginine and elucidating its mechanism of action.
However, ArgHCl is only moderately effective at inhibiting aggregation, thus there is a necessity
to develop more effective additives.
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2.5. Design and Testing Approach
The "neutral crowder" theory and the observed behavior for arginine suggests that
effective association suppressing excipients can be created by synthesizing a relatively large
compound that has functional groups on the surface that interact favorably with protein
molecules, producing a compound that is neither strongly bound nor strongly excluded from the
surface of a protein due to a balance of exclusion and attraction. The background on solution
additives presented above suggests that preferential interaction measurements and thermal
unfolding analysis will be of use in the development of such excipients and thus, they were
utilized to elucidate the mechanism by which the novel excipients influenced aggregation.
In our study, guanidinium chloride was chosen as the protein binding moiety since this
functional group is present on arginine and it is known to bind to proteins. Such compounds were
produced by modifying commercially available amine compounds (e.g. di- and tri-amines (see
Figure 2-6 and Figure 2-7, respectively) and polyamidoamine (PAMAM) dendrimers (see Figure
2-8)). This in addition to synthesizing arginine peptides (see Figure 2-9). Moreover, in addition
to preferential interaction and thermal unfolding analysis, the synthesized excipients were tested
by incubating, at elevated temperatures, a solution containing a model protein in the presence of
the novel excipients and monitoring monomer loss kinetics via size exclusion HPLC.
Tests showed that the first batch of excipients synthesized were unsuccessful at inhibiting
aggregation. In fact, most accelerated aggregation. However, further analysis of the arginine
mechanism revealed that ion-ion interactions are extremely important when it comes to
suppression aggregation and careful analysis must be made when choosing the counterion for the
guanidinium functional group. This led to the production of excipients that not only inhibit
aggregation, but do so with abilities nearly an order of a magnitude great than arginine or any
other commonly used excipient.
NH2  NH2
H2N NH NH NH2
Figure 2-6: An example of a diguanidinium compound.













Figure 2-8: Structure of a Generation 0 PAMAM dendrimer with the surface modified to guanidinium.
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H2N NH2  H2N NH2
Figure 2-9: An example of an arginine peptide for use as an excipient.
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3. Experimental Procedures
One of the initial goals set at the beginning of this project was to establish a set of
procedures and assays that would allow for a proper assessment of the effectiveness of the
synthesized additives, not to mention allowing for the mechanism of action to be elucidated. To
fully understand the results presented in this document, it is essential to be aware of how the data
was collected. Therefore, this chapter is devoted to detailing all of the procedures utilized in
order to provide clarity to the data presented and to eliminate any need for repetition in
explaining the results. For a proper comparison of the data collected, these procedures remained
nearly constant throughout the study and the conditions stated here are the conditions utilized for
all the data presented, unless otherwise stated.
3.1. Proteins and Reagents
Bovine serum albumin (BSA), A3059, hen egg white lysozyme (Lys), L6876, bovine a-
chymotrypsinogen A type II (aCgn), C4879, and jack bean concanavalin A (Con A), C2010,
were obtained from Sigma-Aldrich (St. Louis, MO) as essentially salt free lyophilized powders.
All other reagents used were also obtained from Sigma-Aldrich in the highest available grade.
The concentration of BSA, lysozyme, aCgn, and Con A were determined by absorbance using
extinction coefficients of 0.658 mL*mg~'cm~' at 278 nm, 2.74 mL*mg'icm~l at 281 nm, 1.97
mL*mg~icm'i at 282 nm, and 1.37 mL*mg'icm~' at 280 nm respectively [31]. No corrections
were made for cosolute concentrations or light scattering since the concentrations were typically
low due to the protein solutions being diluted with pure water for the purpose of producing a
sample with an optical density of about 1.0.
3.2. Chemical Synthesis & Purification
3.2.1. General Procedure
3.2.1.1 Synthesis
The general procedure developed for synthesizing the novel excipients involved
converting commercially available amines into guanidine compounds through the use of a
guanylating agent. The synthesis of guanidine compounds has received much attention lately
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because of the biochemical and pharmaceutical importance of the guanidino moiety and a variety
of guanylating agents are commercially available. For more info, Katritzky and Rogovoy have
reviewed the recent developments in guanylating agents [44]. Of the many reagents available for
different guanidinylation purposes, the most applicable reagents are either a thiopseudourea or a
pyrazole carboxamidine because of our desire to synthesize compounds with unsubstituted
guanidines on the outer surface of the compound. The later is a more potent guanylating agent
but the former allows for an easier purification procedure since the leaving group is a volatile
thiol that can simply be evaporated from the solution, on top of being less expensive. Most
reagents come with protecting groups on the nitrogens and a tert-butoxycarbonyl (BOC)
protecting group was chosen (see Figure 3-1) since it allowed for the reaction and purification to
be carried out in an organic solvent (an aqueous phase synthesis was found to be not ideal due to
limited reagent availability and purification options) and is easily removed with a strong acid,





Figure 3-1: 1,3-Bis(tert-butoxycarbonyl)-2-methyl-2-thiopseudourea, the guanylating agent utilized in the
synthesis of the excipients.
The procedure developed and presented here is a modification of the method presented
by Gers and coworkers [45]. The typical procedure involved adding an excess of the
guanidinylation reagent (usually a 1.25-2 fold excess) to a solution containing the amine of
interest dissolved in either dichloromethane (DCM) or dimethylformamide (DMF). All reactions
were conducted in a fume hood since the methanethiol produced not only has a very pungent
odor but can be toxic in high doses. Reaction vessels were left open to the environment to allow
the methanethiol to evaporate from the solution, allowing for a more facile reaction. DCM was
found to be advantageous in some cases since it is highly volatile and thus easily removed
through evaporation prior to purification. However, the substitution reaction involved proceeds
somewhat slowly in DCM and solutions tend to dry out if reaction times are too long, thus it was
only used for the smaller excipients, which reacted more quickly due to fewer substitution sites
per molecule. DMF is better suited for facilitating the substitution reaction (i.e. reactions
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proceeded more quickly) and for longer reaction times since it has a lower vapor pressure.
However, due to this low vapor pressure, the solvent is somewhat difficult to remove from the
solution using a standard laboratory vacuum pump. Therefore, DMF was only utilized when
synthesizing larger excipients.
Solutions were stirred for 8-72 hours with the reaction monitored using thin layered
chromatography (TLC). The TLC plates contained a fluorescent dye, allowing for spots
containing organic compounds to be detected with a UV lamp (254 nm). The TLC mobile phase
contained a mixture of polar and nonpolar solvents in a ratio that gave the best separation of the
reaction system of interest. A typical mixture contained hexane:ethyl acetate:methanol in a ratio
of 1.5:1.25:1. Unreacted amine compounds typically had no mobility due to their polar character,
while the guanylating agent had high mobility due to its nonpolar character. The product (i.e. the
excipient of interest with BOC protecting groups) usually had a low to moderate mobility. When
all of the amine was consumed by the reaction, the solvent was evaporated under reduced
pressure at 60 0C using a rotavap. When DMF was used, only enough solvent was evaporated to
reduce the volume to a reasonable level for the purification step because extended periods of
high temperature and high concentrations of the dendrimer compounds caused the compounds to
degrade and crosslink, producing an insoluble gel.
3.2.1.2 Purification
Several purification procedures were explored during this project. Initially, a polymer
bound version of the guanylating agent was tested since no purification step was required but
such products are expensive and were found to be inefficient at converting all of the substitution
sites to guanidine. A liquid-liquid extraction (LLE) technique was explored but the best
techniques were found to be solid-phase extraction (SPE) for small guanidinium compounds and
precipitation for the dendrimers.
The small amine compounds used as starting reagents are inexpensive and available in
large amounts. The products from these starting compounds are fairly nonpolar and hard to
separate from the guanylating agent. It is much easier separating the product from just the polar
amine compound, however, an excess of the guanylating agent is required for the reaction to go
to completion because all of the compounds utilized contain multiple substitution sites. To
resolve this issue, one option is to add the small amine compounds dropwise, with each drop
added at a rate that allows the previous addition of amine to be completely converted, and
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stopping when all of the guanylating agent is consumed. Another option is to react a known
amount of the amine compound with a slight excess of the guanylating agent to consume all of
the amine, then add a large excess of the amine once the reaction is completed to quickly
consume the excess guanylating agent, thus creating a solution containing a known amount of
the product and a small amount of unreacted and partially reacted amine. Neither procedure is
advantageous in regards to the complexity of the final solution or the conversion rate for a given
amount of the amine compound. However, the later procedure was utilized for simplicity in
regards to the amount of monitoring required and the variability in reaction times (i.e. the rate at
which drops are added must be in accordance to the rate at which the reaction proceeds for
maximum conversion, which at the beginning of this project was unknown and varies depending
on the amine starting compound). After the addition of additional amine, the solvent was
evaporated at atmospheric pressure at 600C and the residue was dissolved in hexane. The
solution was then passed through a SPE column packed with silica to separate the product from
unreacted or partially reacted amine compounds. The unreacted and partially reacted amines
were retained on the column and the product passed right through (as determined by TLC). After
washing the column with hexane, the solvent was evaporated from the collected solution under
reduced pressure at 60'C.
As for the dendrimer compounds, the same procedure could not be utilized due to the
high cost of the dendrimers. Also, SPE was found to be ineffective since the dendrimers had a
high affinity for the silica and they could not be eluted, even with a highly polar solvent.
Furthermore, the dendrimer products were found to be insoluble in hexane due to their polar
character. Therefore, after much of the DMF was evaporated, the residue was dissolved in a
minimal amount of diethyl ether and hexane was added to precipitate the product. The
guanylating reagent was found to be soluble in hexane, thus after discarding the supernatant,
washing the precipitates with hexane, redissolving the precipitates in diethyl ether and repeating
the procedure several times, the product became quite pure (as determined by TLC).
3.2.1.3 Deprotection
The deprotection step removing the BOC protecting group is quite simple. After
purifying the products and evaporating the solvent, the residues were dissolved in a minimal
amount of DCM. Then an excess of 2M HCl dissolved in diethyl ether (sometimes 4M HCl
dissolved in dioxane) was added to the solution. The vials were placed in a fume hood with the
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cap left open to the environment to allow the carbon dioxide formed to escape. The final product
slowly precipitated as the BOC protecting groups were removed. Occasionally, the vials were
agitated or stirred with a Teflon coated spatula. After 24 hours, the precipitates were inspected.
The deprotection was assessed to have been completed when the formation of carbon dioxide
bubbles had ceased for at least two hours and the precipitates had a hard consistency that was
easily ground into a powder (rather than having an amorphous consistency similar to gum).
Following the deprotection step, the precipitates were spun down in a centrifuge, the supernatant
discarded, and diethyl ether added to wash the precipitates. This was repeated at least 8 times (4
washes with diethyl ether and 4 washes with acetone). The precipitates were dried under reduced
pressure at 600C briefly and then dried under reduced pressure at room temperature for 24-48
hours. The structure of the products was analyzed using mass and NMR spectrometry. The purity
was analyzed using NMR spectrometry by identifying the impurities and computing the amount
of each relative to the product.
3.2.2. Ion Exchange
Ion exchange was utilized to prepare alternate salt forms of the synthesized excipients.
An excess of the sodium salt of interest was used to load the anion of interest onto a column
containing Amberlite IRA 400 anion exchange resin. After rinsing the column with HPLC grade
water, a solution containing one of the synthesized excipients or L-arginine hydrochloride was
passed through the column, in an amount less than half of the capacity of the column and at the
recommended flowrate to ensure complete ion exchange. Additional water was then passed
through the column to elute all of the excipient.
3.2.3. Type Specific Procedures
3.2.3.1 Arginine Salts
To help elucidate the arginine mechanism, a variety of arginine salts were produced.
Most of the arginine salt forms of interest are not available commercially and thus they had to be
prepared from L-arginine or L-arginine hydrochloride. Most of the salts (phosphate, sulfate,
citrate, acetate, fluoride, bromide, and iodide) were prepared by titrating an L-Arginine solution
with the appropriate acid solution. Arginine thiocyanate (ArgHSCN) had to be prepared via ion
exchange, as described above, since thiocyanic acid is an unstable compound that is not
commercially available. All arginine salt solutions were completely dried for storage and
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reconstituted at the desired concentration prior to use. Most of the water was evaporated under
reduced pressure at 60'C using a rotavap. The crystals that formed were further dried for at least
48 hours over a calcium sulfate desiccant under reduced pressure. Prior to use, the amount of
residual water was determined by gently heating a small sample (500 mg) at around 120*C until
the mass remained constant. This procedure verified that the phosphate and citrate salts were
monohydrates.
3.2.3.2 Modified Amine Compounds
To summarize the developed synthesis technique, commercially available di- and tri-
amine compounds were guanylated with an excess of the guanylating agent in DCM and a large
excess of the amine was added once the reaction was completed to completely consume the
remaining guanylating agent. The product and unreacted amine were separated using SPE with
hexane as the mobile phase. The BOC protecting group was removed from the purified product
with concentrated HCl dissolved in either diethyl ether or dioxane. The precipitated product was
washed with diethyl ether and acetone and then dried at an elevated temperature and reduced
pressure.
3.2.3.3 PAMAM Dendrimers
To summarize the developed synthesis technique, commercially available PAMAM
dendrimers (generations 0-2) were guanylated with an excess of the guanylating agent in DMF.
After the reaction was completed, most of the DMF was evaporated at 600C under reduced
pressure and the excess guanylating agent was removed by dissolving the residue in a minimal
amount of diethyl ether and precipitating the product with hexane, repeating the procedure until
the product was pure (as indicated by TLC). The BOC protecting group was removed from the
purified product with concentrated HCl dissolved in either diethyl ether or dioxane. The
precipitated product was washed with diethyl ether and acetone and then dried at an elevated
temperature and reduced pressure. Alternate salt forms were prepared via ion exchange, with
excess water evaporated at 600C under reduced pressure and dried to completeness via
lyophilization.
3.2.3.4 Arginine Peptides
The arginine peptides were not synthesized in house. Collaboration with another research
group, which specializes in peptide research, was initiated prior to the beginning of this project.
They were tasked with preparing the peptides. However, their contribution was quite poor. It
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took them nearly a year to figure out which HPLC column to use to purify the peptides. Even
after they determined the proper procedure, they could only provide a few milligrams of peptide
(which was barely enough for a single experiment) every 4-6 months. The purity of the peptides
they produced were questionable and the lyophilization technique they used to convert the
peptides from a TFA to chloride salt was likely ineffective. Due to their poor performance,
customized peptides were later purchased from GenScript@ Corporation, with each batch size in
an excess of 1 gram and purity greater than 98%. LC-MS data was provided to validate the purity
and structure of the peptides. Alternate salt forms, including the chloride salt form, were
prepared via ion exchange, with excess water evaporated at 600C under reduced pressure and
dried to completeness via lyophilization.
3.3. Structural Analysis
3.3.1. Nuclear Magnetic Resonance (NMR) Spectrometry
The structure and purity of the synthesized excipients were analyzed via NMR
spectrometry. The Bruker Avance 400 NMR spectrometer in the Department of Chemistry
Instrumentation Facility (DCIF) was utilized for this purpose. 1D 1H (400 MHz) and ID "'C (101
MHz) spectrums were produced for official validation of the structure. 2D 11-1' H COSY and 2D
'H-"C HSQC techniques were utilized to help deconvolute the ID spectrums. If any ambiguity
persisted, results were compared to predictions made using ChemBioDraw Ultra 12.0. The
guanylating agent and amine precursors were analyzed as well (which also included the amine in
an ammonium chloride salt form for comparison to the guanidinium salt spectrum) to identify
any unreacted precursors. The amine starting compounds and the BOC protected intermediates
were each dissolved in deuterated chloroform (CDCl 3) and the guanidinium salt products and
ammonium salt precursors were dissolved in deuterated dimethyl sulfoxide (DMSO-d6), all at a
concentration around 25 mg/mL. 'H and 13C spectrums were calibrated using residual protio-
solvent. The total integrated area of the 'H spectrums were set to the total number of hydrogens
present on the target molecule. No unreacted amine or guanylating agent were detected, thus the
only impurities were residual solvent, which were identified by comparing chemical shifts with
literature values. The residual solvent peaks were integrated separately from the product peaks to
determine moles of solvent per mole of product, thus allowing a calculation of mass percentage.
(See Appendix A for NMR data for each excipient analyzed).
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3.3.2. Mass Spectrometry (MS)
Several ionization sources are available at MIT for mass spectrometry analysis, but
electrospray ionization (ESI) was deemed best suited to analyze the synthesized compounds
since (1) the technique allows for the analysis of samples with a molecular weight greater than
1000 daltons and (2) of the techniques available for ionizing large compounds, ESI produces the
least amount of fragmentation without the use of a matrix, which can interfere with the analysis
of ions with small mass-to-charge ratios. The DCIF houses a Bruker Daltonics APEXIV 4.7
Tesla Fourier Transform Ion Cyclotron Resonance Mass Spectrometer (FT-ICR-MS) equipped
with an electrospray ionization source. Only positive ions were analyzed (with samples
processed by the facility's mass spectrometry specialist) and the data was deemed satisfactory
when the major peaks corresponded to a [M+nH]"* value, typical of ESI-MS. (See Appendix A
for MS results for each excipient analyzed).
3.4. Model Proteins
The most critical aspect of this project was assessing the effectiveness of the novel
excipients at inhibiting aggregation. Protein aggregation is a complex process that is completely
dependent on the physical and chemical properties of the protein(s) involved. For example, some
proteins are so unstable that nearly all of the dissolved protein will aggregate within a few hours
at room temperature and at a relatively low concentration, while some proteins require near
boiling temperatures to cause them to aggregate, even at high concentrations. Furthermore, the
effect additives have on aggregation is not completely universal, thus any new additive produced
must be tested on all proteins of interest to verify effectiveness. Therefore, a thorough
assessment of the effectiveness of any new excipient would be an extremely difficult and tedious
task. To allow an adequate amount of research and development to be conducted during this
project, testing had to be restricted to one or a few model proteins that are aggregation prone and
representative of pharmaceutical proteins.
Obviously, performing tests using actual pharmaceutical proteins would be ideal.
However, such proteins are very expensive and obtaining an adequate amount would not be
feasible without some sort of collaboration with the manufacturer. Producing a pharmaceutically
relevant protein in-house would be less expensive, but such work is very time consuming and
only a relatively small amount can be produced and purified in a lab setting. A tremendous
amount of protein was required for all of the testing and stability analysis required in this study.
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Therefore, the model protein was restricted to an inexpensive, commercially available protein
that can be obtained in large quantities but also has characteristics similar to pharmaceutically
relevant proteins.
3.4.1. Literature Review and Early Analysis
Many articles that deal with protein aggregation (which is also a topic of interest in other
fields, such as food science, neurological diseases, diagnostics, etc.) have used ordinary proteins
commonly found in most laboratories (e.g. BSA, lysozyme, beta lactoglobulin, hemoglobin,
ovalbumin, ribonuclease A, carbonic anhydrase etc.) for the very same reasons mentioned above
[15, 46-51]. Other articles have utilized more pharmaceutically relevant proteins (e.g. insulin,
human factor VIII, immunoglobulin, human growth hormone, GCSF, human interferon gamma,
etc.), but in most cases, the source of the protein was provided by a pharmaceutical company.
Moreover, in some cases, the aggregation of the particular protein is not of a pressing concern,
other cases showed the aggregation mechanism to be quite complex and for some, the protein
seemed to not be ideally suited for heat induced aggregation studies [52-57].
Early work conducted in this study began with BSA, lysozyme, and carbonic anhydrase.
However, those proteins did not make ideal model proteins because the aggregation kinetics of
BSA were hard to analyze, lysozyme was found to show little aggregation propensity unless
heated to fairly high temperatures, and carbonic anhydrase was a bit more expensive and did not
respond well to high ionic strength. However, after reviewing the literature again, newly
published articles showed that a-Chymotrypsinogen A would make an ideal model protein.
3.4.2. Bovine a-Chymotrypsinogen A
a-Chymotrypsinogen A (aCgn) was selected as a model protein for aggregation because
it is a well characterized protein that has been used extensively as a model protein in aggregation
studies due to it having aggregation characteristics similar to therapeutically relevant proteins
[58-60]. More importantly, the native state is monomeric, with simple unfolding
thermodynamics and kinetics that forms nonnative aggregates on a reasonable time scale at
mildly elevated temperatures.
aCgn is a globular single-domain protein with a molecular mass of 25.7 kDa and an
isoelectric point (pI) of 9.2 (thus it has a positive charge when formulated at physiological or low
pH). The protein is the inactive precursor of the serine protease chymotrypsin. Thermal stability
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Figure 3-2: Denaturation midpoint temperature (Tm) of aCgn versus pH, demonstrating optimal
conformational stability at around pH 4 (figure taken from [61]).
Other studies show that the protein has the greatest colloidal stability (as determined by
osmotic second virial coefficient values) at low pH and low ionic strength [62]. However, at low
pH, the protein is conformationally unstable from being in such a highly charge state and would
be highly aggregation prone if it were not for strong repulsive electrostatic interactions.
Furthermore, at low pH, increasing the salt content has a detrimental effect on colloidal stability
due to the screening of repulsive interactions. At a higher pH, the charged state of the protein is
much lower and is prone to associating due to a lack of electrostatic repulsion. Increasing the
ionic strength screens attractive charge-dipole and dipole-dipole interactions. Thus at high ionic
strength, the pH of the solution has little influence on colloidal stability, similar to other proteins.
These results also show that at around pH 5 (the point at which the dominate interaction
shifts from repulsive electrostatic interactions to attractive dipole interactions), the protein is
least sensitive to ionic strength, thus making this the ideal pH for this study. This is not only
because the protein exhibits the greatest conformational stability at that pH, ionic strength effects
would not contribute to the aggregation of the protein. This would allow for a clearer assessment
of the aggregation suppression mechanism. These results are almost identical to those for
chymotrypsin, which were obtained by a separate research group, indicating that these results are
reliable [63].
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Figure 3-3: Osmotic 2"d Virial Coefficient (B22) values for aCgn (at varying ionic strength) versus pH,
demonstrating that aCgn is least sensitive to ionic strength at around pH 5 (figure taken from [621).
3.4.3. Enzymatic Inhibition and Solution Preparation
It should be noted that the sample of aCgn obtained contains trace amounts of either
chymotrypsin or trypsin, which exhibits proteolytic activity when the pH is greater than 4.5.
When incubated at elevated temperatures, the digestion rate of aCgn is comparable to the rate of
aggregation, leading to a considerable amount of small molecular weight peptides forming over
the course of an experiment and likewise, a considerable amount of the protein lost to digestion
rather than aggregation, making it impossible to determine how an additive influences
aggregation. Lowering the pH was not an option because at low pH, the protein is highly
sensitive to the presence of ions. As described above, a pH of about 5 is optimal for when using
this protein. To verify this, sodium chloride and potassium chloride were used as cosolutes, up to
a concentration of IM, at a pH of 5. Neither salt exhibited any influence on the rate of
aggregation under these conditions. However, this was not the case for when the pH was lowered
to below 4.5. At low pH, all types of salt, including ArgHCl, sped up aggregation, with all types
increasing the rate by nearly the same extent. This indicated that the loss of colloidal stability
resulting from electrostatic shielding dominated any aggregation inhibition the salt compounds
may have exhibited.
Therefore, to keep the protein from being digested, a stock of aCgn was first treated with
phenylmethylsulfonyl fluoride (PMSF), a serine protease inhibitor that irreversibly inhibits
proteolytic activity. 35 mg of PMSF was first dissolved in 1 mL of anhydrous ethanol. This
solution was then added in 250 pL increments to a stirred 50 mL stock solution of aCgn (10
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mg/mL, 100 mM sodium phosphate pH 7) every hour until PMSF reached its solubility limit,
usually after three additions. The higher the pH of the protein solution, the faster the inhibition
reaction proceeds. Likewise, the inhibitor degrades more quickly at high pH due to a reaction
with water, thus a pH of 7 was chosen for an optimal balance of inhibition rate and inhibitor
stability. Moreover, adding PMSF in increments was utilized because the inhibitor, though
effective at low concentrations, still rapidly degrades in aqueous solutions at pH 7 [64]. Three
hours after the first addition of PMSF, the solution was passed through a 0.1 micron filter
(Millipore) to remove PMSF precipitates, then placed under dialysis (Spectra/Por 3500 MWCO)
for 48 hours at 40C against three changes of 20 mM sodium citrate pH 5 buffer (700 mL each).
Following the dialysis, the solution was first centrifuged briefly to remove any aggregates that
precipitated during dialysis and then concentrated using a centrifugal filter (Amicon Ultra 10,000
MWCO) to a final concentration of 20 mg/mL.
This treatment reduced the digestion rate to an insignificant level and all aCgn samples
produced in this manner had nearly identical aggregation rates. All aCgn solutions were frozen,
rather than lyophilized, in 0.3 mL aliquots, and used within 6 months. Storing the protein in this
manner did not seem to have any detrimental effect on the quality of the protein (i.e. the amount
of aggregates in the initial solution) nor the rate of aggregation when used in the study. Solutions
for the aggregation study were prepared by first preparing a solution of the cosolute of interest in
a 20 mM sodium citrate pH 5 buffer at a concentration double that of interest (adjusting the pH
to 5 if needed with the appropriate acid or an 8M sodium hydroxide solution), then mixing 0.3
mL of this solution with 0.3 mL of a thawed aCgn solution. This solution was then divided into
twelve aliquots, each 50 pL in volume, and incubated at an elevated temperature, as described
below.
3.5. Accelerated Aggregation Assay
The rate of aggregation for most proteins is actually fairly slow. At refrigerated or room
temperatures, it may take days, weeks, or maybe even months before significant levels of
aggregates to form, if at all. One of the most obvious signs that aggregation has occurred is when
the solution has turned turbid from the precipitation of high molecular weight oligomers. In some
cases, the extent of aggregation can be verified by monitoring the amount of visible light
obscured. However, this is not the most robust means of monitoring aggregation, because often,
the aggregates will settle to the bottom of the vial or vessel. Furthermore, in many cases, the
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aggregates remain soluble, thus giving no visible indication that aggregation has occurred, in
addition to giving no viable means to remove the aggregates from the solution prior to injection.
However, if aggregates do form, it does not take much for the solution to be deemed
unacceptable. A general rule of thumb is that the maximum amount of protein in the aggregated
state cannot exceed 5% of the total amount of protein. With this restriction, the shelf-life of many
products is relatively short (i.e. a few weeks to several months) which is far short of the 18 to 24
month shelf-life typically desired. Even with a shelf-life of a few days to several weeks, this rate
is far to slow to allow for adequate testing and analysis of the novel excipients. If experiments
were conducted at room temperature, only a few experiments could be tested over the course of a
four year project. Therefore, the rate of aggregation had to be accelerated by stressing the protein
solution, preferably by enough to allow several experiments to be conducted per week.
There are several ways one could destabilize a protein in order to accelerate aggregation
[5]. However, only a few are frequently used during aggregation studies (e.g. elevated
temperatures, extreme pH, shaking and shearing, freezing and thawing, refolding, addition of a
destabilizing chemical, etc.) because these stresses often occur during production and storage.
Elevating the temperature is the simplest method and most relevant to this study since it is the
most representative of formulation conditions. At slightly elevated temperatures, the main effect
is accelerated association because of more frequent collisions between protein molecules.
However, as the temperature is increased further, the conformation of the protein becomes less
compact and ultimately unfolds. This leads to non-Arrhenius behavior, which makes shelf-life
prediction from accelerated conditions extremely difficult, if not impossible within any
reasonable level of certainty, unless a model is developed from low temperature data. In
addition, it is possible for the mechanism of aggregation at elevated temperatures to differ
significantly from normal storage condition and therefore, methods developed for inhibiting
aggregation at elevated temperatures might not be applicable at lower temperatures.
However, the theory developed to guide this research suggests that the excipients
developed will specifically inhibit association and thus they will inhibit aggregation regardless of
the conformational state of the protein. Furthermore, the temperature selected was chosen to be
more than 10*C lower than the onset of unfolding, making the amount of unfolded protein quite
low. However, at such temperatures, the rate limiting step might shift from partial unfolding to
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association due to a rapid increase in the rate at which partially unfolded species develop relative
to the increases in the rate of association.
On a side note, it was initially hypothesized that the "neutral crowder" excipients would
only be effective for when association is the rate limiting step in aggregation. However, upon
further analysis, it is clear that if the excipients slow association to a rate lower than the rate of
partial unfolding (which occurs prior to association), they will be effective for the case when
partial unfolding is normally the rate limiting step, thus making them universally applicable.
3.5.1. Elevated Temperatures
The aggregation of aCgn was accelerated by incubating samples at an elevated
temperature. A temperature of 52.5"C was found to be optimal, in that it was well below the
onset of unfolding but accelerated aggregation enough to allow an aggregation experiment to be
completed in less than a day. This particular temperature value was reached upon by analyzing
aCgn aggregation over a range of temperature values, each separated by a 2.5'C increment. In
addition to all aggregation experiments being conducted at that temperature, all samples
contained 10 mg/mL aCgn, held at pH 5.0 using a 20 mM sodium citrate buffer. 50 gL aliquots
of each protein-cosolute mixture were placed in 0.2 mL PCR tubes and then incubated in a Bio-
Rad MyCycler thermal cycler with a timer initiated when the thermal cycler reached the desired
temperature. Each series contained 12 samples and up to 8 different mixtures were tested at the
same time during any given experiment. Samples were removed periodically and immediately
placed in an ice bath to quench the aggregation reaction. The length of each experiment was
planned so that the extent of reaction was such that at least 20% of the protein aggregated,
making changes in the rate of aggregation pronounced. After at least five minutes in the ice bath,
the samples were briefly spun in a minicentrifuge to remove precipitated aggregates and then
transferred to autosampler vials for HPLC analysis.
3.5.2. Size Exclusion HPLC (SE-HPLC)
15 pL of each aCgn sample were injected into an Agilent 1200 series HPLC, equipped
with a Zorbax GF-250 (4.6x250 mm, 4 micron) size exclusion column and a UV-Vis detector,
during a sequence. The HPLC mobile phase contained 25 mM citric acid monohydrate, 25 mM
sodium acetate, and 200 mM sodium chloride with the pH adjusted to 4.0 using sodium
hydroxide. The flowrate was set at 1 mL/min and samples were monitored at 280 nm.
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Most of the aggregates that formed either precipitated or did not pass through the column,
thus only the monomer concentration was monitored with time. Peak area at each time point was
compared to the peak area for an unstressed sample to create a monomer loss profile normalized
with respect to the initial concentration. Each profile was compared to a profile for a sample
containing no cosolute to determine the change in aggregation rate upon addition of the cosolute.
For a control, each aggregation experimental setup had one protein solution that contained no
cosolute to verify that the baseline aggregation rate remained constant amongst all experiments.
For all aCgn concentrations studied, the aggregation exhibited 2nd order kinetics, thus rate
constants were determined by fitting each data set to a 2nd order rate law.
3.5.3. Cosolute Osmotic Virial Coefficient Measurements
Vapor pressure osmometry was utilized to evaluate intermolecular interactions in
aqueous solutions of the arginine salts. The most frequently used approach to describe
interactions in electrolyte solutions is the ion interaction or virial coefficient model developed by
Pitzer and co-workers [65, 66]. The model accounts for nonideal trends in the osmotic
coefficient, #, which is defined as
In a Osm (4.1)
~vmM, vm
where aw is the activity of water, Mw is the molar mass of water, m is the solute molality, and v is
the stoichiometric coefficient of the solute. For a single MX electrolyte solution, the Pitzer model
can be expressed as
2v v )0 2 (V VX3/2 CM
#A-l=IZMZ, f+ 2 vMvx Bem+ (vv) Cm 2 , (4.2)
V V
where vM and vx are the number of M and X ions in the formula and zM and zx are their respective
charges in electronic units; also v = vM + vx. The other parameters have the form
fo =-A0 12 / (4.3)
11+bI I
BO=p +p83 1)e , (4.4)
where I is the ionic strength and A 4 is the Debye-H ckel coefficient for the osmotic coefficient,
both in the molal concentration scale. The Wescor 5520 vapor pressure osmometer utilized in
this study has no temperature control, but A0 is a relatively weak function of temperature, thus
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the value for water at the standard temperature of 250C was utilized, which is AO = 0.392
(kg/mol)" 2. The parameters a and b can be floated during analysis but they are typically fixed at
2.0 (kg/mol)"2 and 1.2 (kg/mol)1 2, respectively, for all electrolytes [66]. A previous analysis of
ArgHCl utilized these parameter values and as a result, the same was done in this study [67]. The
parameters ff') and ff 1) describe the ionic strength dependence of the second osmotic virial
coefficient, BO, which describes short range binary interactions. CO is the third virial coefficient,
which describes ternary interactions and is typically small and only important at high
concentrations.
In this analysis, the excipients were dissolved in HPLC grade water, with no buffering
component or pH adjustment. A series of samples were prepared gravimetrically and the density
of each solution was determined using an Anton Paar DMA 4500 density meter, accurate to
within 1x10 5 g/mL, to determine both the molar concentration of each solution and the partial
molar volume. ffo), ff 1) and CO were determined by fitting the osmometry data to Eq. (4.2) using
the nonlinear fitting program Igor Pro.
3.6. Preferential Interaction Determination
3.6.1. Dialysis/Densimetry
Dialysis/Density measurements were carried out according to a previously described
procedure [32]. Lyophilized protein was dried in a desiccator at room temperature for 2 days
under reduced pressure to remove trace amounts of water. Five samples of the dried protein were
dissolved at a concentration ranging from 5 to 25 mg/mL in 4 mL of buffer solutions containing
the cosolute at the desired concentration and pH. For the constant molality measurements, 2 mL
of each sample were set aside, tightly sealed, and left at room temperature overnight prior to the
densimetry measurements. In the constant chemical potential experiments, the remaining 2 mL
of each protein sample were transferred to a dialysis bag and dialyzed at room temperature for 48
hours against two changes of solvent (400-500 mL each) prior to densimetry measurements. The
density of each solution was measured using an Anton Paar DMA 4500 density meter, accurate
to within 0.00001 g/mL. After the density measurements, samples of each protein solution were
diluted gravimetrically with water to a final optical density of about 1.0 and the concentrations
were determined spectrophotometrically with a PerkinElmer Lambda 35 UV/Vis spectrometer.
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The partial specific volume of the protein from each experiment was determined using Eq. (3.7)
and these values were used to compute the preferential interaction coefficient via Eq. (3.6).
3.6.2. Vapor Pressure Osmometry (VPO)
3.6.2.1 Preparation of Solutions for VPO Measurements
Osmolality measurements were carried out according to a previously described procedure
[27]. For improved accuracy, all samples were prepared gravimetrically using a Mettler Toledo
balance with a precision of 0.1 mg. Partial molar volume values of the cosolutes (evaluated using
Eq. (3.8)) and density values of the solutions were used to determine concentration. Even though
a three component system was utilized for the derivation of Eqs. (3.15) and (3.18), it was found
that a pH buffering salt was necessary for the measurements, mainly to stabilize the protein
solution and to control the pH of the guanidineHCl and arginineHCl solutions. Since the
concentration of the buffering salt is constant for every sample, not to mention low, it has no
contribution to the computed slopes used in Eqs. (3.15) and (3.18). Therefore, the molal
concentration of the buffer can be lumped together with that of the water and the system can be
treated as a three component system (i.e. solvent, protein, and additive).
Stock solutions of both BSA and lysozyme and stock solutions of the cosolutes were each
prepared in a 40 mM sodium phosphate pH 6 buffer, while aCgn measurements were conducted
in 20 mM sodium citrate buffer, either at pH 3.5 or pH 5.0. Stock solutions of the cosolutes were
used so that a series of samples could be easily produced with varying solute concentrations by
dilution with water and buffer. The protein stock solutions were further purified by placing the
solutions under dialysis for 48 hours at room temperature against two changes of buffer (1 L
each). To obtain the best possible results from the VPO measurements, the protein solutions were
concentrated to within 100-200 mg/mL (depending on the solubility of the protein) using
Amicon Ultra centrifugal filter tubes. To determine the concentration, samples of each stock
solution were diluted gravimetrically with water to a final optical density of about 1.0 and the
concentration determined spectrophotometrically with a PerkinElmer Lambda 35 UV/Vis
spectrometer. It should be noted that the protein stock solutions were stored at 40C and used with
in one week of their preparation.
Eqs. (3.15) and (3.18) require that osmolality measurements for the three component
solution at various cosolute concentrations be taken at a constant protein molal concentration.
However, it is difficult to prepare such solutions and therefore, samples with a constant molar
Chapter 3 - Experimental Procedures
volume were prepared instead. To correct for this, a relationship between constant protein molal
concentration (M2 ) and constant protein molar concentration ([2]), derived elsewhere, was used
to obtain values for the desired parameter [27]:
(8sm/m 3 )2
03 = - - .)j~ (4.5)
1-f [2]V3_
F 1lI- [2]V2
A Wescor Vapro@ vapor pressure osmometer (model 5520) was used for all osmometry
measurements. The instrument was calibrated using 0.1, 0.29, and 1 mol/kg osmolality standards
provided by Wescor. Due to slight drifts in the calibration points, the instrument was recalibrated
after every four measurements and the thermocouple was cleaned daily using concentrated
ammonium hydroxide followed by a rinse with HPLC grade water. Even though the instrument
is designed to measure osmolality readings as high as 3.2 mol/kg, the accuracy of measurements
above the last calibration point of 1 mol/kg is significantly impaired from extrapolating the
calibration curve and increased system noise at high solute concentrations. It was discovered
during the course of such measurements that this error significantly influenced the accuracy of
the results. Therefore, cosolute concentration was limited so that all measurements had an
osmolality at or below 1.2 mol/kg. The data sets for each cosolute included at least 16
individually made solutions (both for the sets with and without the protein). Each sample
contained approximately 80 pL of solution (40 pL of diluted cosolute stock solution and 40 pL
of the protein stock solution). A minimum of three measurements of each solution were made. If
the standard deviation for a particular solution was greater than 2 mmol/kg, more measurements
were taken or another sample was prepared. For a given solute, data representing the dependence
of osmolality on solute molality were fitted by a quadratic equation, with all fitting parameters
floated. Data were weighted by the standard deviation of the individual osmolality measurements
for the same solution using the nonlinear fitting program Igor Pro. Using a cubic function or
other fitting curves did not improve the fitting for any of the data.
3.6.2.2 Determination of the Isoosmolal Preferential Interaction Coefficient (1)
Though the isoosmolal preferential interaction coefficient F,,1 can be determined directly
from osmolality data (via Eq. (3.17)), it is difficult to obtain an accurate measure of the
relationship between osmolality and protein concentration for every cosolute concentration. This
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is mainly due to the fact that osmolality does not change significantly over the available range of
protein concentration. However, the parameter can be approximated by comparing the molal
concentration of the cosolute in the protein solution (m 3) to the molal concentration of the
cosolute in a two component solution at the same osmolality (i.e. the same water chemical
potential) (m3A
rJ;= am3  ~ (M 3  (4.6)
am2 T,P,pi 2
By using such a procedure, the preferential interaction coefficient F,3 can be determined using
both approximation methods from just three series of samples (i.e. a series containing all three
components at various cosolute concentrations, a series of just protein and buffer at various
protein concentrations, and a series of just the cosolute and buffer at various cosolute
concentrations). For more information, see Table B-1 in Appendix B for experimentally
determined partial molar volumes and osmolality dependence on solute molality for two-
component solutions.
3.7. Folding Thermodynamics/Structure Analysis
3.7.1. Differential Scanning Calorimetry (DSC)
The thermodynamic stability of aCgn in the presence of the excipients was determined by
DSC (Microcal VP-Differential Scanning Calorimeter located in the Biophysical Instrumentation
Facility (BIF) at MIT). Each reading began with a minimum of three buffer-buffer up and down
scans (in this case, the buffer also contains the cosolute of interest) to establish a reproducible
thermal history followed by a single protein-buffer up scan. aCgn was analyzed at a
concentration of 1 mg/mL in a 20 mM sodium citrate pH 5 buffer containing the cosolute of
interest and a scan rate of 90"C/hour. The data was analyzed in the MicroCal Origin@ plotting
software. In the analysis, the last buffer-buffer reference scan was first subtracted from the data,
which was then normalized with respect to the protein concentration, cell volume, and scan rate.
The baseline (which was progressed through the peak) was then subtracted from the plot and the
denaturation midpoint temperature, Tm, was taken as the temperature at the peak maximum of
the unfolding event. For each excipient, three concentrations (including zero concentration) were
tested and Tm values with respect to cosolute concentration were fitted to a linear trend.
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3.7.2. Circular Dichroism (CD) Spectrometry
There are additional methods available for determining the transition point of unfolding.
An alternate method utilized was through the use of a circular dichroism (CD) spectrometer
equipped with a temperature control system. The amount of circularly polarized UV radiation a
protein absorbs will depend on its secondary and tertiary structure. At 220 nm, the ellipticity
(which represents the difference in the amount of left and right circularly polarized light
absorbed) for alpha helix and beta sheet structures are distinctive from a random coil. Therefore,
if the circular dichroism of a protein is monitored at 220 nm as the temperature is increased, the
ratio of unfolded to folded protein and the denaturation midpoint temperature can easily
determined from the change in the ellipticity, assuming the ellipticity reaches a constant value
and that this value represents a completely unfolded protein. The BIF possesses an Aviv Model
202 Circular Dichroism Spectrometer equipped with a thermostat that can scan from -100 to
1 10*C.
The advantage of CD spectrometry is that the procedure is fairly straightforward and
allows for rapid measurements (as apposed to DSC, which can take hours or days for a single
measurement). The procedure is often used to determine the effect cosolutes have on the
structure of a protein as well as the unfolding temperature but the procedure is not applicable if
the cosolute absorbs UV radiation, which is the case for guanidinium compounds. This is a major
downside for this project. Similar techniques (such as fluorescence spectrometry) would also
have a similar problem because of the absorbance of UV radiation, thus the technique was found
to only be useful for analyzing the structure of the protein without any cosolute. This did give a
profile of the amount of protein unfolded versus temperature, which was found useful in shelf-
life prediction and determining an optimal incubation temperature.
Chapter 4
4. Elucidating the Arginine Mechanism
4.1. Arginine Hydrochloride (ArgHCl)
As mentioned before, one excipient that has gained much attention lately is arginine
hydrochloride (ArgHCl) [68]. Its ability to greatly improve the refolding yield of proteins was
discovered, nearly by accident, two decades ago, and since then it has been the topic of many
research articles, mainly due to its effectiveness and unique behavior in regards to suppressing
aggregation [15, 17, 69-76]. Arakawa and coworkers have written many research articles and
reviews regarding the abilities and applications of ArgHCl, including its use during protein
production and purification and as a solution additive for other macromolecules [9, 16, 71, 77-
82]. Their collective work provides useful insight into the mechanism of action and highlights all
of the observed behavior gathered thus far for ArgHCl. However, a clear mechanistic
understanding has yet to be determined. Other researchers have conducted additional studies in
an attempt to resolve this issue, but their results still lack a clear mechanistic understanding as
well and often, the mystery is deepened by the discovery of more unique behavior [17, 20, 72-
74].
As described in Chapter 2, what is known about ArgHCl is that it seems to inhibit
protein-protein interactions with little influence on the conformational stability of the protein,
thus slowing association rather than stabilizing the native structure [15, 18, 70]. Some
researchers have attempted to explain this behavior, but no one theory has been generally
accepted because most theories cannot explain all of the observed behavior, not to mention that
there is often a lack of experimental evidence confirming the proposed mechanism of action
[68]. A theory first proposed in our group (see Chapter 2), suggests that arginine is neutral in
regards to preferential interactions, leading to little influence on the folding equilibrium but
eliciting an entropic penalty for when two protein molecules aggregate due to the exclusion of
arginine molecules from the gap formed between two associating protein molecules [15]. The
preferential interaction coefficient values shown below seemed to, for the most part, support this
theory [70]. However, at high concentrations, the preferential interaction of arginine goes from
being neutral or slightly attracted to being highly excluded, and thus, we have to admit that this
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model only describes a simple theoretical molecule, referred to as a "neutral crowder", and
cannot explain all of the complex behavior ArgHCl exhibits, though the "neutral crowder" effect
may play a large role [68, 76, 83]. To elucidate the mechanism of arginine, we began by
performing a preferential interaction study, followed by molecular dynamic simulations, and an
in depth stability study. Various arginine salts were studied as well, demonstrating that ion-ion
interactions may be a contributing factor in the aggregation suppression mechanism.
4.1.1. Comparison between F. 3 1 ] 1 ,J 3, and Literature Values
To evaluate the reliability of the results determined from VPO measurements, which is a
relatively new technique, a comparison was made with data found in the literature (most of
which was determined by dialysis/densimetry measurements, a well established technique).
Table B-2 through Table B-4 (see Appendix B) summarize the preferential interaction
coefficients over the concentration range detailed in the last column of Table B-1, for BSA,
lysozyme, and aCgn, respectively, in combination with five common cosolutes (arginine
hydrochloride, guanidinium chloride, glucose, glycerol, and urea). Theoretically, the preferential
interaction coefficients F.3 and F,,, are independent of protein concentration, which has been
demonstrated elsewhere, thus there was no need to repeat the measurements at other protein
concentrations [27, 84]. To make the comparison with literature values, EP,, was computed
using Eq. (3.19). All of the results shown in Table B-2 through Table B-4 support the assumption
that F01 ,,,P3 is approximately equal to F P3 because there is no significant difference between F,
and F,,,3 values for any protein-cosolute system tested. Therefore, a direct comparison can be
made between 1 3 values measured by VPO and F.41, 3 values measured by dialysis/densimetry.
In the literature, BSA is the most common model protein used in preferential interaction
coefficient studies and therefore, there is more data available for comparison, which makes it the
ideal protein to evaluate the reliability of the VPO methodology. For guanidinium chloride,
glucose, glycerol, and urea, the trends between F, 3 values and cosolute concentration for BSA
computed from VPO measurements are nearly identical to those reported in the literature. This
gives confidence that VPO is a reliable methodology for determining the preferential interaction
coefficient. However, for BSA, the results for ArgHCl differ significantly from the literature
values, as well as for lysozyme, thus making it unclear which values were most representative of
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the preferential interaction coefficient. Thus a repeat of the dialysis/densimetry measurements
was conducted to resolve this dilemma.
4.1.2. Comparison of VPO Results to Dialysis/Densimetry Measurements
The preferential interaction coefficient F,,,,, 3 for arginine was determined by
dialysis/densimetry measurement techniques at two different arginine concentrations for both
BSA and lysozyme (see Table B-5). For comparison, these results were plotted against the trends
computed from VPO measurements in addition to the literature values, as depicted in Figure 4-1.
It is clear that the results determined by dialysis/densimetry measurements conducted in our lab
confirm the VPO results and bring into question the reliability of the literature values. For BSA
(Figure 4-la), both of the values measured by dialysis/densimetry follow the VPO trend, in
particular, the preferential interaction coefficient for ArgHCl is close to zero at low
concentrations and gradually becomes increasingly negative. This differs from the literature
values, which depict the preferential interaction coefficient for arginine as being significantly
greater than zero at low to moderate concentrations, and then decreasing and becoming
increasingly negative at high concentrations.
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Figure 4-1: Comparison of Arginine 'P 3 values, obtained from VPO measurements (A), dialysis/densimetry
measurements (A), and the literature (taken from [851) (E) for (A) BSA and (B) lysozyme.
For lysozyme (Figure 4-lb), the values determined by dialysis/densimetry confirm that
the preferential interaction coefficient for ArgHCl is slightly positive at low concentrations and
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decreases and becomes increasingly negative at high concentrations. This differs significantly
from the literature values, which depict the preferential interaction coefficient for arginine being
negative and somewhat constant over the entire concentration range tested. In addition the
literature values seem to indicate the value for the preferential interaction coefficient is nonzero
at zero arginine concentration, which is an unrealistic result.
Though the new results for BSA do not differ significantly from the literature, they do
differ greatly for lysozyme. The significance of these new results is that they indicate a common
trend in the interaction between arginine and protein molecules, as opposed to conflicting trends
previously reported [85]. That is, arginine seems to be neither strongly bound nor attracted to the
surface of the protein and becomes excluded only at high concentrations. This has never been
observed before and is a result that characterizes arginine as unique among solutions additives
studied.
4.1.3. Interpretation of Preferential Interaction Coefficient Values
These new results for the preferential interaction of arginine, as measured by VPO and
dialysis/densimetry, differ significantly from literature values [85]. This alters the interpretation
of how arginine interacts with protein molecules. Before, based on the literature values for BSA,
many assumed that arginine was a bound additive (except in the case of lysozyme, where it was
thought that the positively charged protein repelled the positively charged guanidinium moiety
on the arginine molecule). The VPO results seem to indicate something different, and in the case
for lysozyme, the opposite trend is observed. For BSA, in the concentration range of 0-0.3 M,
F P3 is approximately zero and gradually becomes negative as the concentration increases. As for
lysozyme, F P3 values seem to indicate that arginine is slightly bound for concentrations less than
0.5 M and then gradually becomes excluded as the concentration increases. However, for both
proteins, FP3 values seem to indicate that arginine is neither strongly bound nor excluded from
the surface of the protein for arginine concentrations less than 0.5 M but becomes excluded at
higher concentrations.
This trend is further exemplified when the preferential interaction of arginine is compared
to denaturing and stabilizing cosolutes. In Figure 4-2, a comparison has been made with urea and
glycerol for all three proteins tested and it shows that preferential interaction coefficient values
for arginine typically fall in between values for urea and glycerol.
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Figure 4-2: Comparison of arginine preferential interaction coefficient values (El) to that for urea (0) (a
preferentially bound and denaturing cosolute) and glycerol (A) (a preferentially excluded and stabilizing
cosolute) for all three proteins tested; (A) lysozyme, (B) aCgn, and (C) BSA.
Our preferential interaction measurements seem to indicate that arginine has little
interaction with proteins. However, these measurements indicate only how a cosolute interacts
with a protein in its native state, but assuming that the trend holds for the unfolded state, arginine
should have no effect on the unfolding equilibrium because it does not significantly perturb the
free energy of either state. However, some results seem to indicate that arginine has a very slight
destabilizing effect at high concentrations for some proteins (including lysozyme) [86]. This
effect, though, is very minor when compared to guanidinium chloride (1 M arginine HCl
decreases the melting temperature by about 1 C for lysozyme versus a decrease of about 13-17
*C for guanidinium chloride at a similar concentration). Those results seem to indicate that
arginine has a very slight affinity for the unfolded or partially unfolded state but not enough to
have a significant effect on the folding equilibrium.
4.1.4. Relationship of Arginine Preferential Interaction with Concentration
An interesting trend can be observed when the arginine preferential interaction
coefficients for all three proteins tested are plotted together. Figure 4-3 reveals that not only is
there a unique trend in the preferential interaction coefficient for arginine with concentration but
there is also a trend with protein size as well. F.3 values for a-Chymotrypsinogen (a 25.7 kDa
protein) fall in between the values for lysozyme (a 14.3 kDa protein) and BSA (a 66.4 kDa
protein). Since there is no clear trend with the charge of the protein (i.e. the positively charged
arginine seems to be most attracted to the positively charged proteins), these results seem to
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Figure 4-3: Comparison of arginine preferential interaction coefficient values for all three proteins tested
demonstrating the relationship with arginine concentration and protein size; lysozyme, 14.3 kDa (0), aCgn,
25.7 kDa (0), and BSA, 66.4 kDa (A).
The reason for this behavior is not quite clear from this data. It has been shown that
arginine interacts with amino acid residues in almost the same fashion and to almost the same
extent as guanidinium, with both compounds showing a strong affinity for most residues,
especially aromatic residues [9]. This behavior may explain why arginine shows a slight affinity
for proteins and a slightly stronger affinity for unfolded proteins, since aromatic residues are
typically buried in a folded protein. However, surface tension also increases with increasing
arginine concentration, much more so than with guanidinium [9]. Such behavior tends to repel
additives from the protein surface and enhance the binding of water, since the protein surface
constitutes a solvent interface at which there must be interfacial tension. This, in addition to the
fact that arginine is a much larger molecule than guanidinium (i.e. the solvation layer
surrounding a protein molecule that is inaccessible to the additive but accessible to water
increases as the size of the additive increases) further increases the relative repulsion of arginine
with respect to protein size. Thus, the attraction the guanidino residue of arginine has for the
protein surface plus the repulsion generated by the greater surface tension increment and the
greater size may account for why arginine is neither strongly attracted nor strongly excluded
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from the protein at low to moderate concentrations. In other words, arginine experiences a
balance of attraction and repulsion from the protein surface. Also, the fact that arginine becomes
increasingly excluded as the size of the protein increases and is not strongly attracted to the
unfolded state, indicates that the repulsion effects are more dominant than the attractive effects
since guanidinium tends to be more attracted to proteins as the size increases (i.e. there is more
surface area to bind to as the size of the protein increases).
However, the attraction that guanidinium residues have for a protein and the repulsion
generated by surface tension increments and volume exclusion tend to be linear with cosolute
concentration at low concentrations. Therefore, if the affinity and repulsion experienced by
arginine is additive, then the preferential interaction coefficient should display a linear trend with
respect to arginine concentration. However, this is clearly not the trend shown in Figure 4-3. If
arginine has a similar affinity for the protein as guanidinium but at the same time, such
interactions are hindered by surface tension and steric exclusion effects, then it might be possible
for the protein surface to become saturated with arginine at a low concentration if the protein
does not unfold to allow for more binding. If this happens, any additional arginine added to the
solution upon saturation would be merely portioned away from the local domain around the
protein.
The phenomenon exhibited in Figure 4-3 was furthered studied within the group through
the use of molecular dynamic simulations. The work of Diwakar Shukla shows that the varying
level of interaction arginine exhibits with different proteins is due to the number of interacting
groups present on the surface of the protein, not with the size of the protein. Lysozyme has more
amino acids present on its surface which favorably interact with arginine, thus the higher level of
interaction [83]. Furthermore, the hypothesis of arginine saturating the surface was found to be
only partially true. Only at high concentrations (>1.5 m) does the surface become saturated and
therefore, saturation cannot explain the trend observed at moderate concentrations. MD
simulations revealed that arginine tends to form clusters in solution, even at moderate
concentrations, which tend to reduce preferential binding [76]. A more in depth explanation is
provided below.
Chapter 4 - Elucidating the Arginine Mechanism
4.2. Arginine and the Hofmeister Series
4.2.1. Background on Ion-Ion Interactions
When reviewing the literature regarding arginine and protein aggregation, it becomes
apparent that little attention has been devoted toward other salt forms besides chloride. The
chloride form has been studied so exclusively that ArgHCl is often referred to simply as arginine
[68]. Given how much is known about the influence various anions have on protein stability, a
study of other salt forms seemed necessary. The Hofmeister Series,
F- > SO4- > HPO- > Acetate- > Citrate- > Cl~ > NO3 > Br~ > I- > SCN-
NH4 > K* > Na' > Cs* > Li' > Mg2 . > Ca2 . > Ba2 + > Gdm*
first published in 1888, ranks common ions with respect to their ability for precipitating proteins
(greatest precipitation ability (lowest protein solubility) on the left, lowest precipitation ability
(highest protein solubility) on the right), which in turn is related to the thermodynamic stability
of the native state (with a trend opposite of protein solubility) [87]. The series has been studied
extensively since the time of Hofmeister and serves as the foundation for selecting salts that will
influence protein solubility, crystallization, denaturation, and aggregation, though the mechanism
for this behavior is not well understood [88-91]. It has been clearly demonstrated that the choice
of anion has a more pronounced effect on these properties than the choice of cation.
Furthermore, chloride is often placed in the middle of the series, thus other arginine salt forms
are likely to exhibit a drastically different behavior, both positively and negatively, in regards to
protein stability [91, 92].
From an extensive literature search, the only other form of arginine studied in this context
has been ArgH(S0 4)1/2, though the extent of those studies is somewhat limited [93, 94]. Recently
though, the combination of arginine hydrochloride with sodium glutamate was studied by two
different research groups and has received much attention due to a seemingly synergetic effect
when the two solutes are combined in an equimolar ratio [3, 95, 96]. Moreover, in a recently
published review, Lange and Rudolph (Rudolph being one of the researchers who discovered the
arginine effect) postulated, based on existing information, on how other arginine salt forms
would behave as excipients and also commented on the refolding behavior of the sulfate and
phosphate salt forms, stating that those two forms of arginine perform poorly as refolding
excipients even though sulfate and phosphate often provide conformational stabilization [68].
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However, no citations or experimental results were given to support those findings. Even though
sulfate and phosphate may reduce the refolding abilities of arginine, we have found that they
enhance its aggregation suppression ability when a model protein is aggregated under accelerated
conditions. Moreover, switching to a thiocyanate salt induces rapid aggregation under similar
conditions rather than enhancing aggregation suppression, opposite of what we and Lange and
Rudolph hypothesized.
When attempting to explain the arginine mechanism, many researchers start by
addressing the effect of the guanidinium moiety [86, 94]. Indeed, the guanidinium functional
group must play an important role, because not only is arginine the only amino acid with a
guanidinium moiety, no other amino acid exhibits aggregation suppression characteristics quite
like arginine, though other amino acids, particularly proline, have been used as stabilizers [47,
97, 98]. However, without a clear understanding at the molecular level, not only of the
interaction of arginine with protein molecules, but also of how arginine behaves in solution, the
arginine mechanism will remain a mystery.
Recently though, two key revelations, in relation to the solution behavior of guanidinium
and arginine, may help to resolve this perplexing question. The first comes from a series of
articles published by Mason and coworkers, in which they studied the solution behavior of
various guanidinium salts [99-104]. They initially aimed to explain the denaturing ability of
guanidinium but ultimately revealed that guanidinium can form a strong attractive interaction
with various anions of similar size that also have hydrogen bond accepting capabilities (e.g.
sulfate, carbonate, etc.), which likely explains why some guanidinium salts (e.g. guanidinium
sulfate) stabilize proteins rather than denature them because the two ions form clusters in
solution rather than bind to the protein surface [103]. The hydrogen bonding interactions and
cluster formations they demonstrated reveal a lot about the behavior of guanidinium. However,
some of this behavior was revealed long before the work of Mason and coworkers. Bonner, using
osmotic coefficient data and Raman spectroscopy, gave valuable insight into the hydrogen bond
interactions between guanidinium and halide ions over three decades ago [105, 106]. Bonner
showed that guanidinium and fluoride form a strong hydrogen bond, possibly even a partial H-F
bond, in solution and this interaction is weaker for other halides in the order of Cl- > Br~ > F, due
to ion size and charge density. At the time though, these results were used to speculate on the
hydrogen bond formation between guanidinium and proteins. More importantly, Mason and
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coworkers also revealed that the structure of the poorly hydrated guanidinium molecule allows
the positively charged ions to associate, with the planar molecules stacked on top of each other
[100]. These results contradict long held beliefs about how certain cosolutes influence the
structure of water (solutes have long been labeled either a chaotrope or a kosmotrope because of
this water structure viewpoint) and how the perturbed water structure influences protein stability.
[91]. However, their results are compelling and have strong implications for explaining the
arginine mechanism, not only with how arginine will interact with various counterions, but how
an arginine molecule interacts with other arginine molecules (and glutamate), given that
guanidinium should have a strong interaction with the carboxylate moiety found on both
molecules.
A H4,H H2B,H,, 4B H12 H 02
2 21 H"2HN0 
01
NaH 11 H HVMH 4 ~~~~ ~ ~ ~ r .4..
4 k I*~ 4 c\AHaj
I I I, I, I, H2 1,N\H4 l/
( '02 , tz
I 1 2 H31  zH,H I H12 i
1_10 ' __- ,Q H43 H ".N 3  ,C3 H,3
H1 6.1N 1 2c 4. N.
H21  IH22 H H6 - N i' 
4
Figure 4-4: Arginine dimer formation. (A) Head-to-Tail orientation in which the guanidinium moiety
hydrogen bonds with the carboxylate moiety of a nearby arginine molecule, (B) Tail-to-Tail orientation in
which the carboxylate moiety hydrogen bonds with the amine moiety of a nearby arginine molecule, and (C)
Head-to-Head orientation in which the faces of the guanidinium moiety stack on top of each other and the
carboxylate moiety of one molecule hydrogen bonds with the amine moiety of the other molecule. Figure and
results produced by Diwakar Shukla from MD simulations.
This self association of arginine (see Figure 4-4), the second revelation mentioned, has
previously been revealed and has been studied extensively in our lab through molecular
dynamics (MD) simulations [72, 76, 83, 107]. These simulations show that the guanidinium
functional group does indeed interact with the surface of a protein molecule in a fashion similar
to free guanidinium; however, this functional group also forms attractive interactions with other
arginine molecules, particularly with the carboxylate moiety. This self association of arginine
molecules likely prevents arginine from binding too strongly to the surface of protein molecules,
preventing it from denaturing the protein but at the same time preventing protein-protein
interactions. Support for this claim comes from the observation by us and others that if the
carboxylate moiety is not present, the resulting molecule denatures proteins much like
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guanidinium [68]. This self association also explains the unique trend observed for preferential
interaction coefficient measurements (i.e. slightly bound at low concentrations but highly
excluded at high concentrations) and explains why the arginine effect diminishes at high
concentrations [70]. Therefore, we were motivated to explore other arginine salt forms, not only
with the aim of discovering a better performing excipient, but to further our understanding of this
mechanism and how guanidinium-anion interactions may contribute to the observed behavior.
4.2.2. Aggregation Suppression
The aggregation suppression exhibited by various arginine salt forms was tested and an
example of the data collected during an accelerated aggregation experiment is shown in Figure
4-5a. In the figure, the aCgn monomer loss profiles for four different arginine salt solutions are
shown (with all arginine salts at a concentration of 150 mM) in addition to the reference profile
(i.e. no cosolute). It can be seen that ArgH(H 2PO4), ArgH(Citrate)1 2 , and ArgHCl reduce the rate
of aggregation, while ArgHSCN increases it. The rate of monomer loss in the presence of
ArgHCl at 150 mM is approximately twice as slow as the reference monomer loss rate.
However, at the same concentration, ArgH(Citrate)u 2 and ArgH(H 2PO4) slow the rate by a factor
of approximately 3 and 8, respectively. On the other hand, ArgHSCN at 150 mM increases the
rate by a factor of 6. This, however, only represents a fraction of the data collected, which is best
represented in Figure 4-5b. The figure shows the relative rate constant for monomer loss (i.e. the
rate constant relative to the rate constant for no cosolute) over a wide range of cosolute
concentrations. It should be noted that the profile for ArgH(H 2PO 4) is limited due to its poor
solubility (approximately 0.45 M at room temperature).
The results shown in Figure 4-5b demonstrate that phosphate, sulfate, and citrate
significantly improve the aggregation suppression ability of arginine when compared to chloride.
More importantly, at low concentrations (less than 150 mM), the aggregation suppression ability
of ArgH(H 2PO4) is significant. At a concentration of 150 mM, the rate of aCgn aggregation in
the presence of ArgH(H 2PO 4) is 2.5 times slower than when in the presence of either
ArgH(S0 4)1 /2 or ArgH(Citrate)1 2. However, the aggregation suppression ability of ArgH(H 2PO4)
levels off significantly as the concentration is increased beyond 200 mM and the aggregation
suppression ability of ArgH(S0 4)1,2 and ArgH(Citrate)1 2 likely exceeds it at concentrations
above 300 mM. As will be discussed below, this trend seen for ArgH(H 2PO4) is likely the result
of the strong interaction between the guanidinium moiety of arginine and the phosphate ion.
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These interactions seem to cause arginine-phosphate clusters to form at higher concentrations,
leading to high preferential exclusion and a strong thermodynamic stabilization but also limited
cosolute solubility and reduced association suppression.
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Figure 4-5: The influence of arginine salts on aCgn monomer loss due to aggregation at 52.5*C. All solutions
contained 10 mg/mL aCgn and were prepared in a 20 mM sodium citrate pH 5 buffer. (A) Monomer
concentration, M, normalized with respect to the initial monomer concentration, MO, versus time from a
single experiment, with plots fitted to a second order rate law. The concentration of each arginine salt shown
was 150 mM. (B) aCgn monomer loss rate constant in the presence of a cosolute, k, relative to no cosolute, ko,
versus cosolute concentration, with lines drawn through the plots to aid the eye.
As for the remaining arginine salts to the left of chloride in the Hofmeister Series, the
relative rate constant for fluoride and acetate are essentially the same as that for chloride. At
concentrations below 100 mM, the aggregation suppression ability of these three salt forms are
comparable to sulfate and citrate. However, as the concentration increases, the aggregation
suppression ability of sulfate and citrate continue to improve, having a relative rate constant
value between 0.02-0.04 at the highest concentration tested (0.5 M), while the relative rate
... . .......... .... ....... ....... ..
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constant for fluoride, acetate, and chloride levels off, having a near constant value of about 0.2
for concentrations above 0.4 M. ArgHF seems to level off the least and has a slightly better
relative rate constant value at a concentration of 0.5 M, which will likely improve slightly as the
concentration is increased further, however, such concentrations are considered quite high and
would rarely ever be used.
As for the arginine salts to the right of chloride in the Hofmeister Series, relative rate
constant values for bromide remain fairly close to unity for all concentrations tested, while
iodide and thiocyanate have nearly identical profiles, which show a large increase in the rate of
aggregation, up to 10 times faster at a concentration as low as 200 mM. The relative rate constant
for ArgHBr dips down to around 0.7 at 150 mM before reversing and exceeding a value of 1 at
higher concentrations. This indicates that the slight denaturing effect of bromide balances out the
aggregation suppression effect of arginine, while the strong denaturing effect of iodide and
thiocyanate completely overpower the effect of arginine. The large size and low charge density
of these ions lead to them being poorly hydrated and therefore, in thermodynamic terms, they
tend to partition to the surface of a protein rather than being solvated in the bulk solution, even
more so if hydrophobic residues are exposed [99]. This favorable preferential interaction leads to
protein denaturation, with iodide and thiocyanate having a stronger preferential interaction than
bromide due to their smaller charge density. In fact, iodide and thiocyanate are so destabilizing
that ArgHI and ArgHSCN are stronger denaturants than guanidinium chloride (GdmCl), as
represented by relative rate constant values (see Figure 4-5) and the denaturation midpoint
temperatures (see discussion below). The relative rate constant for GdmC1 initially decreases
when it is added to the solution (similar to ArgHBr), reaching a minimum of about 0.6 at 200
mM and then increases there after, reaching a value of 9 at 0.7 M, the highest concentration
tested. This shows that at low concentrations, GdmC1 has an ability to reduce aggregation by
inhibiting protein-protein interactions, similar to arginine, but at high concentration, the
denaturing effect of this compound dominates and causes aggregation to proceed more rapidly.
However, ArgHI and ArgHSCN show no stabilizing effect from the presence of arginine. They
instead increase the rate of aggregation at all concentrations tested, doubling the rate at a
concentration as low as 50 mM. All of this exemplifies the pronounced effect the choice of anion
has on protein stability and shows that ArgH(H 2PO4), ArgH(S0 4)1/2 and ArgH(Citrate)1/ 2 might
be more useful than ArgHCl for preventing protein aggregation.
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4.2.3. Conformation Stability
The thermodynamic stability of aCgn in the presence of the arginine salts was assessed
by determining the change in the denaturation midpoint temperature, Tm, with respect to cosolute
concentration. Table B-6 shows the denaturation midpoint temperature increment, dTm/d[3],
defined as the slope of Tm with respect to the molar concentration of the cosolute (component 3),
over the concentration range tested, as determined by DSC. This parameter allows for a
comparison to be made amongst the different cosolutes since it describes the rate at which Tm
changes per amount of cosolute added. Over this short initial concentration range, Tm exhibited a
linear trend, giving constant values for dTm/d[3]. The values obtained exhibit the pronounced
effect the anions have on the thermodynamic stability of the protein and they correspond directly
to ordering of the relative rate constants obtained during the aggregation study.
However, as has been mentioned above, conformational stabilization is not the only thing
to consider when assessing how a cosolute influences aggregation. From the simple model
provided in Chapter 2, it is clear that there are two types of additives which will deter
aggregation: conformational stabilizers and association suppressors. As shown in Table B-6,
ArgH(H2PO4), ArgH(S0 4)1 /2 and ArgH(Citrate)1 2 increase the melting temperature of the protein
at a rate of 6.3, 5.4, and 3.3 'C*M-1, respectively. Clearly, these salts are able to stabilize the
native structure of the protein and inhibit the formation of partially unfolded species. This
thermodynamic stabilization is on top of the association suppression effect of arginine, leading to
the significant aggregation suppression shown in Figure 4-5. However, ArgH(Acetate), ArgHF,
and ArgHCl exhibit no thermodynamic stabilization, which is consistent with previous reports
for ArgHCl, thus these salts inhibit aggregation solely through an association suppression
mechanism. ArgHBr, on the other hand, has a denaturing effect on aCgn, lowering the melting
temperature at a rate of 7.7 0C*M-1. This reduction in conformational stability, which increases
the number of reactive species in solution, seems to nearly balance out the association
suppression effect of arginine, as exhibited by the relative rate constant having a value near unity
over a wide concentration range. This reduction in thermodynamic stability is only slightly
greater than that for GdmCl, which might explain why they have near identical profiles at low
concentrations. However, the association suppression effect of arginine seems to be greater than
that for guanidinium, thus, at high concentrations, the rate of aCgn aggregation is higher in the
presence of GdmCl than in the presence of ArgHBr. As for the other arginine salts, ArgHI and
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ArgHSCN lower the melting temperature significantly, both with a rate greater than 20 *C*Ml.
This denaturing effect overpowers the association suppression effect of arginine and as a result,
these salts increase the rate of aggregation at all concentrations. These results, along with
aggregation suppression data, support the claim that ArgH* acts as an association suppressor and
shows that the choice of anion will either enhance or counteract this aggregation suppression by
influencing the stability of the native structure.
4.2.4. Ion-Ion Interactions
As mentioned above, ion-ion interactions may be contributing to the observed behavior
of the arginine salts. To quantify this behavior, osmotic 2nd virial coefficient values were
determined for aqueous solutions of the arginine salts via VPO and MD simulations.
Experimental osmotic data were analyzed using the Pitzer model, while MD simulations were
analyzed using the McMillan-Mayer model. Pitzer ion interaction parameters for each of the salts
are shown in Table B-6. The second virial coefficient parameters obtained for ArgHCl closely
matches values reported in the literature. However, the value for the third virial coefficient
differs. This is likely due to the narrow and low concentration range used in this study. The third
virial coefficient is typically small and is only important at high concentrations. Moreover, much
of the time, it can be excluded from the model with little error. Therefore, there is greater
uncertainty in the third virial coefficient values reported here and they are not likely to accurately
represent trends at high concentrations. However, the second virial coefficient parameters
reported are likely to be a fair representation of behavior in the concentration region of interest.
Since the magnitude of like and unlike ion interactions is ionic strength dependent, it is
generally held that only cation-anion binary interactions make contributions to the value of p)
(see Eq. (4.4)). Both like and unlike ion interactions make contributions to fiP, making it
difficult to interpret this parameter unless radial distribution functions are available for each ion
pair. The trends observed for p') are in accordance with the discussion above. The values for the
phosphate, sulfate, and citrate salts are large and negative, indicating a strong interaction
between arginine and those anions. The value for ArgHCl is negative but smaller in magnitude,
indicating a weak attractive interaction. The values for the other halide salts show repulsive
interactions for those salt forms with the strongest repulsion for thiocyanate and iodide and the
weakest for bromide. These trends are similar to those for guanidinium halide salts, which show
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a weak repulsive interaction with fluoride, a moderate repulsive interaction with bromide, and a
strong repulsive interaction with iodide [67].
During MD simulations performed by Diwakar Shukla, significant ion pairing was
observed in the aqueous arginine salt solutions, which supports the above experimental results.
Ion-pairs in thiocyanate, chloride and acetate solutions are observed to be randomly distributed
throughout the solution while citrate, phosphate and sulfate show a marked tendency to form
hydrogen bonded clusters. Snapshots of the MD simulation boxes of arginine salts are shown in
Figure 4-6. It can be seen that the structures formed by sulfate, citrate and phosphate salts are
worm-like chains of sizes comparable to the box-size. Clustering observed in chloride,
thiocyanate and acetate solutions is mainly due to Arg-Arg interaction, as reported in our recent
work on aqueous arginine hydrochloride solutions [76, 108]. Similar ionic clusters were also
observed in aqueous guanidinium salt solutions [100-102]. Brady and coworkers have shown
that clustering in Gdm salts is not dependent on the choice of the water model and is not a
simulation artifact. Due to the presence of Gdm group as a side-chain in arginine, the clustering
behavior of arginine salts is expected to be similar to Gdm salts. The only difference between
Gdm and arginine salts is the presence of additional charged groups and a carbon chain in
arginine. These additional charged groups (N-terminal amino group and C-terminal carboxylate
group) seem to further enhance the clustering in solution.
Radial distribution functions (Figure 4-7) between pairs of ions help to further
characterize the solution structure. Arg-Arg pairing, as illustrated by the RDF between the Gdm
carbon atoms in the arginine molecule (Figure 4-7a), shows a tendency of the Gdm side chain to
stack with each other or form ion-pairs separated by the anion acting as a bridge between two
Gdm side chains. The presence of an anion does not significantly affect the Arg-Arg pairing
except in the case of citrate, where the large size of the anion crowds out the formation of Arg
pairs. The pairing between cation and anion is strongest for the sulfate ion due to the
exceptionally strong interaction with the Gdm group (Figure 4-7b). Acetate also has a strong
interaction with arginine; however, the interactions for thiocyanate and chloride are weak and
almost nonexistent. The pairing between anions (Figure 4-7c) is significantly weak, as compared
to other ion pairs in solution. Phosphate ion pairing exhibits a peak around 0.5 nm due to the
presence of hydrogen bonding acceptors and donors in the same molecular anion. Sulfate also
shows a peak around 0.6-0.7 nm but this is not due to direct interaction between sulfate ions;
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rather, the peak is due to the presence of multiple sulfate anions associating with adjacent or the
same arginine cation.
Figure 4-6: Snapshots of the MD simulation box containing arginine salts at a concentration of 0.5 mol/kg.
To improve the clarity of the image, water molecules are not shown and only heavy atoms (all atoms
excluding hydrogen) in the arginine molecules and counter-ions are shown. The following color code is used
to represent atoms: C (cyan), 0 (red), N (blue), S (yellow), Cl (light blue), and P (brown). Arginine molecules
are shown in silver. Figure and results produced by Diwakar Shukla.
.................. ... ............... .................. .
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Figure 4-7: Radial distribution functions (RDF) between ion-pairs in aqueous arginine salt solutions. Cation-
Cation RDF is the RDF between guanidinium carbon atoms of arginine. For the counter ions, the atoms used
as centers for estimating the RDF's are: Sulfate - Sulfur atom, Phosphate - Phosphorus atom, Citrate -
Central carbon atom, Thiocyanate - Nitrogen atom and Acetate - Carboxylate carbon atom. Figure and
results produced by Diwakar Shukla.
The individual contribution of specific ion-pairs to the overall clustering in the solution
can be estimated by calculating the osmotic second virial coefficient between ion-pairs in
solution from MD simulation results. B22 values for ion-pairs in each salt solution are reported in
Table 4-1, which show a similar trend to the experimentally obtained Pitzer coefficient data. It
can be seen that the contribution of cation-cation interaction is similar in magnitude to cation-
anion interaction. Iij denotes the sum of interactions between all ion pairs. Sulfate, phosphate
.............. ..  .
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and citrate form a group with strong overall interactions whereas chloride, thiocyanate and
acetate form a group with weak overall interactions. The difference between the collective
structures of these two groups of anions apparently results from the differences in the hydrogen
bonding of the anions to the arginine cation.
Table 4-1: McMillan-Mayer Second Virial Coefficient, B22 (L/mol), values for ion pairs in aqueous arginine
salt solutions. Results produced by Diwakar Shukla.
Arg Salt C B22  B22  B22  Eij
(mol/L) ++ +- --
(S04)1/2 0.49 -6.58 -4.63 -4.89 -20.73
(Citrate)1 2 0.48 -2.13 -3.24 -0.35 -8.96
(H2 PO4) 0.48 -3.20 -2.00 -1.60 -8.80
(Acetate) 0.48 -1.80 -1.25 -0.2 -4.50
Cl 0.48 -0.99 -0.90 0.45 -2.35
SCN 0.48 -1.40 -0.90 0.40 -2.80
The numbers of hydrogen bonds between different ion-pairs in solution, as determined
from MD simulations, are reported in Table 4-2. It can be seen that the highest number of
hydrogen bonds between arginine molecules are formed in chloride and thiocyanate solutions
due to the minimal interaction of these ions with the cation. The loss of hydrogen bonds between
arginine molecules in acetate, sulfate, phosphate and citrate solutions is compensated by the
formation of large number of cation-anion hydrogen bonds. Acetate also interacts strongly with
the arginine, forming hydrogen bonds with the Gdm group as shown in Figure 4-8a, but due to
the limited number of hydrogen bond acceptors, the acetate anion cannot act as a bridge between
multiple cations. On the other hand, citrate, sulfate and phosphate can form bridged structures, as
shown in Figure 4-8b, c, and d, respectively. The number of hydrogen bonds between arginine
ions (with an anion acting as a bridge) is high for sulfate, phosphate and citrate as compared to
acetate, chloride and thiocyanate, which have limited to negligible capacity to form such bridged
structures.
These observations also explain why sulfate, phosphate and citrate form large hydrogen
bonded clusters in solution as compared to acetate, chloride and thiocyanate. These results are in
accordance to our previous reports, in which we showed that ArgHCl likely forms Arg-Arg
clusters in solution at high concentration, which leads to a higher preferential exclusion.
Moreover, according to the "Gap Effect" theory developed in our group, this clustering reduces
the ability of individual ArgHCl molecules to inhibit protein-protein association, however, this is
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likely compensated for by the association suppression ability of the large clusters [10, 15, 72, 76,
83].
Table 4-2: Number of hydrogen bonds between different ions in aqueous arginine salt solutions. Results
produced by Diwakar Shukla.
Arg Salt C Cation- Cation- Anion- Anion-
(mol/L) Cation Anion Anion Arg-Anion
(SO 4)11 2  0.49 42.7 51.3 0 67.3
(Citrate)1 2 0.48 35.8 31.7 0.4 28.2
(H2P0 4) 0.48 40.6 30.1 11.7 19.5
(Acetate) 0.48 29.3 30.6 0 8.3
Cl 0.48 49.4 6.3 0 0
SCN 0.48 38.2 4.0 0 0
(a) (b)
Figure 4-8: Hydrogen bonding interaction between arginine and (a) acetate, (b) citrate, (c) sulfate and (d)
phosphate anions. It can be seen that sulfate, phosphate and citrate can interact with multiple arginine
molecules forming large hydrogen-bonded structures. The following color code is used to represent atoms: C
(cyan), 0 (red), N (blue), S (yellow), and P (brown). Results produced by Diwakar Shukla.
4.2.5. Preferential Interactions
To gain insight into how the arginine salts inhibit protein-protein interactions, the
preferential interaction coefficient, FP3' at various concentrations was determined, both
experimentally via VPO measurements and computationally via MD simulations. The
experimental results are depicted in Figure 4-9, which shows F,3 values at various cosolute
concentrations, and Table B-6, which summarizes the polynomial fit and uncertainty of the
experimental data. It should be noted that the preferential interaction coefficient could not be
obtained via VPO for the acetate and fluoride salts due to these anions being in equilibrium with
their respective conjugate acid forms at pH 5. This is because both of these acid forms are
I I --- - ---- - --- -- I ........... ......... .............
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volatile and this volatility (even though it is slight due to the low concentration of the conjugate
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Figure 4-9: Preferential Interaction Coefficient, r~3, values for the interaction between arginine salts (and
guanidinium chloride for comparison) and aCgn, as determined from VPO measurements. Error bars left off
for clarity and curves drawn through the plots to aid the eye (see Table B-VI for more detail).
Regardless, the experimental results for the other salts show a clear difference between
the anions to the left and to the right of chloride in the Hofmeister Series. The chloride, bromide,
iodide, and thiocyanate salts all have preferential interaction doefficient values that start out
positive at low concentrations, with an initial slope almost identical to GdmCl, whereas the
initial values for the citrate, sulfate, and phosphate salts are negative. The preferential interaction
data for GdmCl is depicted in Figure 4-9 and Table B-6 as well for comparison, which exhibits a
linear trend with respect to concentration.
The initial slope for the chloride, bromide, iodide, and thiocyanate salts show that at low
concentrations, when there is likely little ion-ion interactions, the salts interact favorably with the
protein surface, with an attractive interaction similar in strength as that for GdmCl. However, as
the concentration increases, the preferential interaction coefficient values for all of these arginine
salts begin to decrease and ultimately become negative, whereas the trend for GdmCl continues
to increase linearly, indicating that at high concentrations, these arginine salts exhibit a net
repulsive interaction with the native protein structure, opposite of what is observed for GdmCl.
Furthermore, the preferential interaction coefficient values for thiocyanate and iodide salts
exhibited the largest values at all concentrations, followed by bromide and chloride, indicating
that the thiocyanate and iodide ions cause those salts to have a stronger attractive interaction with
the protein surface, followed by bromide, which causes only a slightly stronger interaction.
. .............
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This nonlinear trend is in accordance with previously reported values for ArgHCl and
aCgn, with values differing slightly due to a difference in pH [70]. In our previous report, the
surprising behavior exhibited by ArgHCl was initially thought to be the result of the protein
surface quickly becoming saturated with the large molecule. MD simulations later revealed that
this hypothesis was likely true but only at much higher concentrations (>1.5 m) and thus another
mechanism contributed to the nonlinear trend observed at lower concentrations [76, 83]. As
mentioned before, studies of aqueous ArgHCl solutions revealed that arginine has a strong
propensity to form clusters in solution via hydrogen bonding between the guanidinium and
carboxylate moieties, which was found to be stronger than the hydrogen bond formed with water,
and as a result, it reduces the interaction with the protein surface. This reduced interaction is due,
in part, to the larger net size of the clusters (steric exclusion) but in large part, is due to a
favorable interaction with other arginine molecules in the bulk solution, which is similar or
greater in strength as the interaction with the protein surface. This self interaction is
concentration dependent, with more clustering obviously occurring at higher concentrations, and
is observed for all arginine salts, thus leading to the nonlinear trends shown in Figure 4-9.
Even though for most cosolutes there is a direct relationship between the preferential
interaction coefficient and the folding stability of the protein, there are, however, some
exceptions [26]. The mechanism for each exception varies but all are the result of preferential
interactions being repulsive in one conformational state and attractive in another. For compounds
containing guanidinium and halide anions, exceptions can arise due to the exposure of
hydrophobic residues upon unfolding. Guanidinium, the larger halides, and thiocyanate have a
strong preference for hydrophobic residues which causes them to interact more strongly with the
unfolded state and as a result, they denature proteins [99]. That is, if they are not inhibited from
interacting with the protein surface, as in the case for arginine. The preferential interaction
coefficient values obtained experimentally and MD simulations seem to indicate that arginine is
inhibited from interacting strongly with the protein (either with the native state or the unfolded
state) even though it has a guanidinium moiety, but the halide anions and thiocyanate are free to
interact with the protein. This favorable interaction is in order of SCN~ ~ F > Br~ > Cl~, as
indicated by Tm and F P3 results. The interaction between F- and the protein is likely similar in
strength as that for Cl-, which is weak at best, but as explained above, FP3 could not be
determined for ArgHF.
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The magnitude of the interaction with the protein for these salts not only arises from a
difference in the protein-anion interaction but also from a difference in the guanidinium-anion
interaction, as discussed above, with thiocyanate and iodide exhibiting a weaker interaction with
guanidinium. Thus these ions are less likely to interact with arginine in the bulk solution.
Fluoride and chloride not only exhibit a weaker interaction with the protein surface, but they also
interact more favorably with the guanidinium functional group on arginine. Therefore, as a result
of Arg-Arg interactions and weak Arg-anion interactions, FP3 values exhibit a nonlinear trend for
all of the salts discussed and due to the variation in Arg-anion and protein-anion interactions, the
magnitude of FP3 and the shift in Tm varies amongst the salts. ArgHCl and ArgHF are neither
naturants nor denaturants because there is little difference between the interaction with the native
and unfolded states. When a protein unfolds, free ArgH* will likely interact more strongly with
the exposed hydrophobic residues but the clusters should become more excluded, counteracting
this interaction. The interaction of the fluoride and chloride ions with the unfolded state likely
does not change much because of the weak interaction these ions have for hydrophobic residues
or interfacial surfaces. As for ArgHBr, ArgHI, and ArgHSCN, the interaction with the unfolded
state is stronger due to an increase in surface area and the stronger interaction the anions exhibit
for hydrophobic residues, leading to those salts denaturing proteins.
The salts to the left of chloride in the Hofmeister series exhibit similar interactions but of
differing magnitude, resulting in F, 3 trends distinct from the other salts. The phosphate, sulfate,
and citrate salts have F P3 values that start out negative and remain negative, with values similar
to other highly excluded solutes (e.g. glycerol), indicating that the salts have a strong repulsive
interaction with the protein at all concentrations [70]. ArgH(S0 4)1 / is the least excluded of these
salts, causing the ordering of F7P3 data to differ slightly from the ordering of Tm data. Also, the
profile for citrate is almost linear for most of the concentration range, likely from the large citrate
ion interfering with Arg-Arg clustering and being highly excluded. It is well documented that
salts with these anions typically stabilize the folded state, as is the case for the data shown here.
Both this and the preferential exclusion can be contributed, in part, to the nonspecific repulsive
interaction of the anions with protein molecules that result from the ions being well hydrated and
preferring the bulk solution. But as discussed above, phosphate, sulfate and citrate have been
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shown to exhibit a strong interaction with guanidinium, which further reduces the interaction
with the protein.
Theoretical preferential interaction coefficient values computed from the MD simulation
are reported in Table 4-3. The estimated preferential interaction values match well with the trend
in the experimental values. The experimental and computational estimates for sulfate, phosphate
(if linearly extrapolated to 0.5m) and citrate indicate large, negative preferential interaction
coefficient values, while thiocyanate exhibits a large, positive preferential interaction coefficient
value. The experimental and computational estimates do not match exactly, which is likely due
to the inability of the force field to capture the interactions of these ions with the protein surface.
Force fields are optimized for interaction of ions with water molecules. However, as shown
above, for arginine salts, interactions with water is only one of the key interactions. In order to
obtain an accurate estimate of preferential interaction coefficient values, force fields for
electrolytes should also be benchmarked to reproduce bulk solution properties and interactions
between individual ions [109, 110]. For the purposes of understanding the interesting
experimental trends observed in this study, the current force fields provide reasonable estimates
of the trends in the data.
On the basis of the preferential interaction coefficient of individual ions, it can be
concluded that the number of cations on the protein surface is related to the number of anions.
Thiocyanate ions have large positive preferential interaction coefficient values but it does not
interact strongly with arginine cations. Sulfate ions have a negative preferential interaction
coefficient but it interacts strongly with arginine. Therefore, there are two driving forces that
push and pull arginine towards and away from the protein surface. In order to conserve the local
charge near the protein surface, more arginine molecules are drawn towards the protein surface if
there are a high number of anions near the protein surface. If the interactions between ions in the
bulk solution are not as strong as compared to the interaction between the ion and the protein
surface, the ions accumulate near the protein surface. Therefore, sulfate, phosphate and citrate
salts have a large negative F,3 because of their exclusion from the protein surface and the strong
interaction with arginine molecules, which pulls arginine away from the surface. The opposite
can be said for thiocyanate, acetate and chloride salts.
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Table 4-3: Theoretical preferential interaction coefficient values for a-Chymotrypsinogen A in aqueous
arginine salt solutions. MD results produced by Diwakar Shukla.
Arg Salt C F 0  TMD F+ - Protein-Arg
(mol/L) h-bonds
(SO 4 )1 /2  0.5 -5.2±1.7 -4.5 -4 -3 15.3
(Citrate)ui2  0.5 -7.7 1.5 -4.5 -4 -3 16.1
(H2PO4) 0.2 -5.7+0.4 -3 -2 -4 10
(Acetate) 0.5 N/A 0 1 -1 19.7
Cl 0.5 -2.6±0.3 -2.5 -1 -4 18.9
SCN 0.48 0.2 1.2 4 4 4 26.5
The error bars on the preferential coefficient values are on the order of ± 1
This interaction between arginine and the anion further reduces the preferential
interaction of the arginine salt with the surface of the protein and further limits interactions with
the unfolded state, thus enhancing thermodynamic stabilization. This cation-anion interaction
does not necessarily reduce Arg-Arg interactions though, because the anion bridges together two
arginine molecules, similar to guanidinium-sulfate clusters discovered by Mason and coworkers,
causing the nonlinear trend observed [101]. Therefore, the ordering of the l.3 and Tm data is not
only ranked by how the individual anions interact with protein molecules but also, with how
those anions interact with the guanidinium functional group on the arginine molecule.
The trends discussed here are related to the impact these salts have on protein
aggregation. As discussed in the previous section, both changes in the folding equilibrium of the
protein and changes in protein-protein interactions must be taken into consideration. The halide
and thiocyanate salts exhibit an attractive interaction with the protein at low concentrations. This,
according to the theory developed by Baynes and Trout, should reduce protein-protein
interactions, much more so for arginine than for guanidinium due to the larger size of arginine
[10, 15]. However, as discussed before, bromide, iodide, and thiocyanate also denature the
protein, which counteracts this effect. This is not the case for chloride and fluoride, thus ArgHCl
and ArgHF reduce aggregation solely through a reduction of protein-protein interactions.
However, at high concentrations, the ArgHCl shows a net exclusion (which is likely the case for
ArgHF and ArgH(Acetate) as well but to a lesser extent) and the aggregation suppression ability
of ArgHCl plateaus because adding more ArgHCl at that point does not contribute any to
protein-protein interaction suppression due to the additional arginine molecules being partitioned
to the bulk solution. Even though ArgHCl shows a net exclusion at high concentrations, there are
enough arginine molecules in the local domain of the protein for it to significantly reduce
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protein-protein interactions, thus lowering the relative rate constant to about 0.2. This indicates
that the effect from the arginine molecule should be significant for the highly excluded salt forms
as well, though the effect of arginine reducing protein-protein interactions might be reduced
some. Furthermore, aggregation suppression is further enhanced for the excluded salts via the
stabilizing effect the citrate, sulfate, and phosphate salt forms have on the folding equilibrium,
leading to the relative rate constant being further reduced beyond that for ArgHCl. Moreover,
another contributing factor may be an increased diffusional barrier. The cluster formation
induced by the phosphate, sulfate, and citrate ions likely increases the viscosity of the solution in
addition to forming a network of bridged ions around the protein, thus inhibiting the movement
of protein molecules. This mechanism has not been considered before and should be further
investigated since it will likely be a key feature of novel excipients.
4.3. Conclusions on the Arginine Mechanism
For arginine salt solutions, we have shown that the interaction between ions and the
interaction of the anion with the protein surface influences the preferential interaction coefficient
value, which is directly related to the conformational stability of the native state. Attractive ion-
ion interactions in solution lead to the formation of clusters that are larger in size as compared to
the individual ions. This effective size enhancement of the molecules around the protein
increases the "Gap effect" and inhibits protein-protein association. Furthermore, clustering
should lead to an increase in the viscosity of the solution, which should lower the diffusion of
proteins in solution. Therefore, ion-ion interactions affect the rate of aggregation via three
mechanisms: 1) enhancing the native state conformational stability, 2) increasing the barrier for
protein-protein association, and 3) increasing the viscosity of the solution medium. These results
not only help to elucidate the arginine mechanism, they also have large implications for
interpreting the mechanism behind the Hofmeister Series, in that, changes in the water structure
did not seem to come into play. Rather, ion-ion interactions and other ion specific behavior seem
to dominate the behavior of each arginine salt.
Chapter 5
5. Novel Excipient Development
As described in previous chapters, protein aggregation is a major problem in the biotech
industry, which not only affects the development and production of therapeutics but also affects
the use of diagnostic proteins. As a consequence, there is interest in improved methods of
stabilizing protein based products, which has motivated us to synthesize and test a novel class of
solution additives with aggregation suppression abilities significantly greater than currently used
excipients. In an attempt to accomplish such a goal, we set out to produce so called "neutral
crowder" additives. It was theorized that by balancing the attraction between a protein and
guanidinium with the exclusion generated by volume exclusion effects observed for large
molecules, a new class of additives could be created that would inhibit protein-protein
association with little influence on the conformational stability of the protein. As described
below, we created new molecules by modifying the surface of large molecules through the
addition of multiple guanidinium functional groups. We later showed that with the proper choice
of counterion, the synthesized molecules behaved as aggregation suppressors. For our model
proteins, the new compounds fulfilled the main goal of the project, in that they lower the rate of
aggregation by an order of magnitude more than commonly used excipients. We feel that this is a
positive result in the right direction and hopefully, the compounds will perform equally well for
other proteins.
5.1. Structure of Synthesized Compounds
5.1.1. Modified Amine Compounds
The first series of compounds synthesized were simple diguanidinium compounds. We
synthesized such compounds so that different design features could be explored and assessed
(i.e. size and number of guanidinium functional groups) to aid in the development of larger, more
complex structures. Figure 5-1 depicts the general structure for one type of simple compound
(i.e. diguanidinium compounds), which are numbered as In, where 1 represents a single
hydrocarbon chain with n number of carbons. A variety of diguanidinium compounds were
synthesized, ranging from the smallest size possible (i.e. a 2 carbon chain labeled 102) to the
largest soluble compound, about 12 carbon units, which was labeled 112 (see Figure 5-2).
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Figure 5-2: Structures and reference number of all the Di- and Triguanidinium compounds synthesized.
Larger guanidinium compounds were synthesized, with either 2 (2n series) or 3 (3n
series) hydrocarbon chains attached to a central amine functional group (see Figure 5-2). Both
series produced a compound with three guanidinium functional groups, thus they are referred to
as triguanidiniums. The variety of commercially available amines is limited, especially for the
triamines, thus the type of compounds that could be produced in this manner is somewhat limited
unless the amine compounds are synthesized from scratch. Figure 5-2 represents nearly all of the
compounds that could be produced from commercially available amines. There were a few other
compounds that were tested, mainly amine compounds that contained hydroxide functional
groups, but the use of those compounds was limited due to difficulty in purifying the product.
5.1.2. PAMAM Dendrimers
The most promising starting materials to work with are dendrimers, specifically
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dendrimer). These molecules are repeatedly branched (each branch contains an amide functional
group, which gives the branches rigidity) and are roughly spherical in shape, not to mention large
but still soluble in aqueous solutions. The properties of dendrimers are dominated by the
functional groups on the surface of the molecule. In the case of PAMAM dendrimers, the surface
functional groups are amines, which can easily be converted to guanidinium groups via the
methodology described in Chapter 3. Dendrimers are classified by generation (i.e. the number of
repeated branching cycles that are performed during syntheses). Each subsequent branching
nearly doubles the size and molecular weight of the molecule (see Table 5-1), thus making them
an ideal starting material to produce excipients with a radius greater than 8 A (which was a
benchmark size set at the beginning of the project).
Table 5-1: Size and molecular weight of PAMAM Dendrimers
Generation Core MW Diameter Surface
Carbons Daltons A Groups
0 2 517 15 4
1 2 1430 22 8
2 2 3256 29 16
3 2 6909 36 32
It should be noted that there is some ambiguity in the literature in how generation naming
is applied. The naming shown here follows how the manufacturer (Dendritech@) names each
generation, which is to refer to the starting amine compound (usually ethylene diamine) as the
core and to refer to the first dendrimer structure produced as Generation 0 (some sources refer to













Figure 5-3: Generation 0 polyamidoamine (PAMAM) dendrimer, with an ethylene diamine core and
guanidinium chloride surface groups (GO-Cl)
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Figure 5-4: Generation 1 polyamidoamine (PAMAM) dendrimer, with an ethylene diamine core and














Figure 5-5: Generation 2 polyamidoamine (PAMAM) dendrimer, with an ethylene diamine core and
guanidinium chloride surface groups (G2-Cl)
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Figure 5-3 through Figure 5-5 depict the surface modified dendrimers structures
produced (initially all structures were chloride salts). As shown in the figures and later confirmed
by NMR (see Appendix A), the internal branch points are protonated as well, thus the additional
counterions in excess of the number of surface groups. The core of the dendrimer can vary but
there is no variation in the branch structure. A core size of 2, 4, 6, or 12 carbons are commonly
available from Dendritech@. In addition, Starburst@ offers a PAMAM dendrimer with ammonia
as the core structure (these dendrimers have 3 initial branches and are commonly referred to as
Starburst@ polymers). Only dendrimers with an ethylene diamine core were utilized in this study
(see Table 5-2 for the molecular weight of the protonated excipients and the entire molecular
weight of various salt forms).
Table 5-2: Molecular weights of guanidinium modified PAMAM Dendrimers (including total molecular
weight for various salt forms).
Generation Core Surface MW Total Molecular Weight of Salt
Carbons (Protonated) CI- S0 42- H2 P0 4
0 2 GdnH* 690.9 903.6 979.1 1272.8
1 2 GdnH* 1780.3 2276.6 2452.7 3138.1
2 2 GdnH* 3959.0 5022.6 5400 6868.7
5.1.3. Peptides
Another promising class of molecules is arginine peptides. These molecules are simple to
produce and were expected to have enhanced aggregation suppression properties over ordinary
arginine. The peptides produced were synthesized either by our collaborators or purchased from
Genscript. Most of the results presented depict data collected using the GenScript@ peptides as
excipients. Figure 5-6 depicts the structures of arginine peptides ranging from a dimer to a
tetramer, though peptides up to a heptamers were synthesized and tested.
NH NH2  NH; NH2  H2N NH2  NH2 NH2
NH NH NH NH
0 0 0 0 0
NH O H3N NH O NH NH
HN' 0 NH 0- HN* NH 0-
0 =0 -0 0
NH NH NH NH NH
H2N NH2  H2 N NH2  H2N NH2  H2N NH2  H2N NH2
Dimer Trimer Tetramer
Figure 5-6: L-Arginine peptides.
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Table 5-3: Peptides obtained from Genscript@ Corporation.
Peptide MW Molecular Weight of Salt
Daltons HCl H2SO4
RR 330.4 403.3 428.5
RS 261.3 297.7 310.3
RL 287.4 323.8 336.4
RQ 302.3 338.8 351.4
RE* 303.3 -- --
RRR 486.6 596.0 633.7
RER* 459.5 496.0 508.5
ERE** 432.4 -- --
RRRR 642.8 788.6 838.9
RREE* 588.6 -- --
RERE* 588.6 -- --
*These peptides are amphoteric and therefore, should exist as a zwitterion without the need of a counterion
**This peptide requires the presence of a cation to neutralize the charge.
Other peptides besides all arginine residues were synthesized and tested. To gather a clear
picture of the effects from changing a single residue, dimers were created with one arginine (R)
residue and the second residue either serine (S), leucine (L), glutamine (Q), or glutamic acid (E).
To mimic and enhance the behavior of arginine-glutamate mixtures, trimers and tetramers were
produced containing different arginine and glutamic acid sequences (RER, ERE, RREE, and
RERE). See Table 5-3 for a complete list of the peptides obtained from GenScript@ and see
Appendix A regarding purity and structural data. Once it was discovered that the aggregation
suppression behavior was strongly controlled by the counterion, studying different sequences
was ended so adequate work towards studying the effect of different counterions could be
conducted. Furthermore, the synthesis and purification of other peptide sequences did not turn
out well since the peptides containing arginine and glutamic acid could not be dried via
lyophilization. The cake structure would always collapse, leaving behind a viscous liquid that
could not be dried any further.
5.2. Aggregation Suppression Behavior
5.2.1. Chloride Salt Form
As mentioned previously, all excipients were initially prepared as chloride salts. A
chloride salt was chosen because most excipients of this nature that are salts come in the chloride
form (e.g. NaCl, guanidinium chloride, Arginine Hydrochloride, etc.) in addition to the fact that
the chloride ion has a negligible preferential interaction and anhydrous HCl is one of the few
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strong acids available dissolved in an organic solvent, the other being trifluoroacetic acid.
Therefore, making a chloride salt from a BOC protected guanidine is only one of a handful of
options without having to perform an ion exchange. It was somewhat apparent that the
counterion might have an impact on preferential interactions; however, the initial strategy for
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Figure 5-7: The influence of diguanidinium compounds (in the form of chloride salts) on aCgn monomer loss
due to aggregation at 52.5"C. All solutions contained 10 mg/mL aCgn and were prepared in a 20 mM sodium
citrate pH 5 buffer. Figure depicts the Relative Rate Constant (as determined by changes in the half life of
aCgn monomer loss) versus additive concentration, with lines drawn through the plots to aid the eye.
In short, all excipient forms initially produced failed to inhibit aggregation. In fact, all
induced aggregation, speeding up the process at moderate to high concentrations. Figure 5-7
depicts the relative rate constant for aCgn aggregation in the presence of diguanidinium
compounds. All of the diguanidinium compounds shown are chloride salts and exhibit a behavior
very similar to guanidinium chloride. That is, the compounds inhibit aggregation at low
concentrations but speed up the process at concentrations above 0.4 M. The compounds are more
effective than guanidinium chloride or arginine hydrochloride at low concentrations (-0.05 M),
but that window of aggregation suppression is narrow and not ideal. Arginine hydrochloride, on
the other hand, continues to inhibit aggregation as its concentration is increased, until ultimately
reaching a plateau. Furthermore, the larger the diguanidinium compound, the more destabilizing
the effect. The 109 and 112 compounds are not shown because they sped up aggregation so
...... .  ........
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rapidly that an observable amount of aggregation occurred at room temperature prior to
incubation.
The arginine peptides exhibit an almost identical behavior. Figure 5-8 depicts the relative
rate constant for aCgn aggregation in the presence of arginine peptides (chloride salt forms). The
figure looks less dramatic because the concentration range is shorter; however, the crossover
point from the concentration range in which aggregation is suppressed to the concentration range
in which aggregation is induced is nearly identical, roughly 0.3-0.4 M. The arginine peptides also
outperform arginine at a concentration of 0.05 M (similar to the diguanidinium compounds and
to almost the exact same extent). Moreover, the larger the arginine peptide, the more it
destabilizes the protein.
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Figure 5-8: The influence of arginine peptides (in the form of chloride salts) on aCgn monomer loss due to
aggregation at 52.50C. All solutions contained 10 mg/mL aCgn and were prepared in a 20 mM sodium citrate
pH 5 buffer. Figure depicts the Relative Rate Constant (as determined by changes in the half life of aCgn
monomer loss) versus additive concentration, with lines drawn through the plots to aid the eye.
The guanidinium modified dendrimers (chloride salt forms) also exhibit this behavior
(see Figure 5-12 in the next section for some of the data collected). Furthermore, all of these
excipients lower the unfolding temperature of the protein, as determined by DSC, which gives an
indication of how they are speeding up aggregation. Even if they do inhibit association, they are
also shifting the unfolding equilibrium to the unfolded state, counteracting any association
suppression. All of this behavior is opposite of what was expected, making it clear that the
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mechanism involved in the preferential interaction is more complex than previously thought. It
was initially thought that the large size of the compounds would counteract the preferential
interaction of the guanidinium functional group due to steric exclusion, but in reality, the large
size seems to enhance the preferential interaction. The problem with the initial theory was that
the design plan was too simple and assumed that such molecules would be rigid spheres instead
of soft, flexible molecules (which is what was synthesized). Moreover, the initial theory assumed
that guanidinium was attracted to protein surfaces in a nonspecific manner, which is not the case
since guanidinium has a stronger preference for buried hydrophobic groups. Figure 5-9 gives a
simple overview of how soft, flexible structures influence preferential interactions and why
monomeric arginine does not exhibit this behavior. In essence, instead of inhibiting interactions,
the large size and flexible nature allows for multiple interactions that bind cooperatively, more so
to the unfolded state. In other words, when one functional group interacts with the surface, it
seems reasonable to assume that it makes it much more likely that a second functional group will
interact due to the proximity between the second functional group and the surface of the protein
brought on by the initial interaction. And once 2 functional groups interact, the process likely
cascades until all possible functional groups are interacting with the protein. Moreover, for larger
compounds, it seems more likely for other functional groups to find a place to bind on the
surface (smaller molecules might not have the reach to bind to another spot on the surface and
large molecules likely diffuse away from the protein at a slower rate). Therefore, large, soft
molecules with many guanidinium functional groups bind to the surface of proteins (or the
unfolded state) with an affinity stronger than anticipated.
Arginine Peptides/
Dendrimers Diguanidinium Compounds
Flexible Backbone/Core The Longer the Chain
Allows for Multiple Length, the More Likely
Guanidinium Groups to Both Guanidinium Groups
Cooperatively Interact Cooperatively Interact





Limited Interaction Due to Single Guanidinium Group and Self
Interaction (Which Also Enhances Crowding).
*Supported by MD Simulations of Arginine and Arg-Glu Mixtures
Figure 5-9: A simple diagram depicting the hypothesis for why the novel excipients destabilize proteins.
........... - .".
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MD simulations seem to support these conclusions. The preferred orientation of
diguanidinium compounds was found to be parallel with the protein surface, indicating that they
lay flat on the surface with both functional groups bound. Experimental evidence for this
hypothesis was recently published [111]. New molecules with guanidinium surface groups
(arginine peptides and polyether dendrimers) were found to have a very strong interaction with
proteins (in this case BSA) and were deemed "molecular glues" by the authors since they
strongly induced protein association. The interaction was strong enough to be determined by
isothermal titration calorimetry (ITC), indicating association rather than preferential binding.
Moreover, the interaction became stronger as the size was increased (i.e. larger dendrimer) and
the flexibility improved (a triethylene glycol linker was introduced into the peptide structure,
which increased the extent of association). These results seem to support the hypothesis of
cooperative binding.
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isothermal titration calorimetry (structures and data obtained from [111]).
Our early work with arginine-glutamate mixtures indicated that the attractive interaction
between the two molecules leads to reduced binding to protein molecules, which reduces the
conformational destabilization and enhances aggregation suppression by creating large clusters
that behave as "neutral crowders". Attempts were made to mimic this behavior but it quickly
became clear that a better or more universal method would be to exchange the chloride
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counterion with an ion that favorably interacts with the guanidinium functional group (see
Chapter 4 in regards to how the counterion influences the behavior of arginine).
5.2.2. Guanidinium-Carboxylate Mixtures
The structure of the diguanidinium compounds is quite similar to arginine and it is
apparent that if one wants to add another compound to the solution that will interact with the
diguanidinium compound in a fashion similar to the interaction between arginine and glutamate,
the best candidate would be a dicarboxylate (see Figure 5-11). Fortunately, dicarboxylic acids
are commercially available and inexpensive. Initial aggregation studies on smaller compounds
showed that the best results came from a 50/50 mixture of a diguanidinium (chloride salt) and a
dicarboxylate (sodium salt) both with identical carbon chain lengths. Such mixtures exhibited
enhanced aggregation suppression (similar in ability to ArgHCl) when compared to either
component by itself. However, such results were limited to the smaller compounds because
mixtures containing diguanidinium and dicarboxylate compounds with a chain length greater
than 3 carbons were nearly insoluble, even though either component was completely soluble by
itself at all concentrations tested (between 0.5-1.0 M). This insolubility gives strong support to
the hypothesis that the two molecules favorably interact in solution and from these results, it
seems that the attractive interaction is quite strong. The hydrogen bonding and electrostatic
interaction between the two end groups, in addition to the hydrophobic interaction between the
two core hydrocarbon chains, likely induces a strong attractive interaction between the two
molecules, causing the mixture to precipitate out of solution.
NH2  NH2
H2N t NH NH NH2
0 0
Figure 5-11: An example of the attractive interaction between diguanidinium and dicarboxylate molecules.
To make the situation worse, dicarboxylate (sodium salt) compounds with a chain length
greater than 7 carbons were found to be insoluble as well, limiting the options for this approach.
An attempt was made to test mixtures in which the two components had differing sized
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hydrocarbon chains. The solubility of the mixtures containing larger compounds was improved
slightly by this approach and such mixtures did exhibit an ability to suppress aggregation.
However, the approach was limited as well, not too mention that it could not be implemented for
other excipient types, such as peptides and dendrimers. Furthermore, it became apparent that the
choice of counterion would produce the same effect (see Chapter 4); therefore efforts were
directed toward studying the effect of exchanging the counterion. On a side note, the solubility of
such compounds could possibly be improved by utilizing a more hydrophilic core structure (such
as polyethylene glycol) but such compounds would have to remain small. This is due to the fact
that for two compounds to associate in the manner desired, the structure would have to be linear
and the number of surface groups would be limited to two or three guanidiniums.
5.2.3. Other Salt Forms
From the literature review presented in Chapter 4 and the results obtained from the
diguanidinium-dicarboxylate mixtures, it became apparent that if the chloride ion was exchanged
with phosphate, sulfate, or acetate, conformational destabilization would be reduced and
aggregation suppression would be enhanced as a result. The work conducted by Mason and
coworkers showed that guanidinium and sulfate interact so strongly that they form large clusters
in solution. As a result, it was initially feared that the solubility of the excipients would be
reduced by the formation of a network of compounds bridged together by sulfate or phosphate
ions. Initial tests showed this to be true for the diguanidinium compounds (in addition, arginine
phosphate has a low solubility as well, indicating a strong interaction). All diguanidinium
compounds, except 103, precipitated completely when Na2 SO 4 was added to the solution,
indicating a strong interaction and cluster formation. However, when mixed with Na2HPO 4, the
smaller diguanidinium compounds (102-104) precipitated right away while 105 turned slightly
cloudy and 106 and larger compounds remained clear. When mixed with NaH2 PO4 , compounds
102-103 precipitated while the rest remained clear, indicating a stronger interaction with HP0 42-
as predicted.
These results of lower solubility only seem to be limited to the diguanidinium
compounds, likely due to the hydrophobic attraction between the molecules and relative ease of
forming a crystalline structure due to the simple structure of the compound. The solubility of the
dendrimers is not reduced by either sulfate or phosphate and the solubility of the arginine
peptides is not reduced by sulfate either. However, the solubility of the peptides in the presence
Chapter 5 - Novel Excipient Development
of phosphate was not tested due to the low solubility of arginine phosphate and the limited
supply of arginine peptides. The performance of the dendrimer and peptide excipients in the
form of other salt types is significantly different from the chloride salt form. Exchanging the
chloride ion with acetate moderately improves the performance of the generation 0 dendrimer
(see Figure 5-12). The acetate salt form has a profile similar to the chloride salt, in that at low
concentrations it inhibits aggregation but as the concentration increases, the trend reverses and
ultimately speeds up aggregation at high concentrations. The only difference is that the relative
rate constant is lower than the chloride salt form for all concentrations tested.
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Figure 5-12: The influence of guanidinium modified PAMAM dendrimer salts on aCgn monomer loss due to
aggregation at 52.5*C. All solutions contained 10 mg/mL aCgn and were prepared in a 20 mM sodium citrate
pH 5 buffer. Figure depicts the Relative Rate Constant (as determined by the amount of time for 20%
monomer loss) versus additive concentration, with lines drawn through the plots to aid the eye.
When the chloride ion is exchanged with either S0 42- or H2PO4, the performance of the
dendrimers is significantly improved. As shown in Figure 5-12, at low concentrations, both the
sulfate and phosphate salt forms lower the rate of aggregation to a greater extent than either the
chloride or acetate salt forms. Furthermore, as the concentration increases, this trend continues
but begins to plateau at a concentration near 0.2 M. At such a concentration, the relative rate
constant is approximately 0.02, which is an order of magnitude better than the relative rate
constant for arginine. This trend continues for larger dendrimer forms, with the larger dendrimers
outperforming the generation 0 dendrimer, as expected. As shown in Figure 5-13, the relative
rate constant profiles for the generation 1 and generation 2 phosphate dendrimers are similar to
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the profile for the generation 0 dendrimer, but the relative rate constant is lower for all
concentrations, with the generation 2 dendrimer exhibiting the lower relative rate constant
profile.
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Figure 5-13: The influence of modified PAMAM dendrimers (guanidinium phosphate monobasic surface) on
aCgn monomer loss due to aggregation at 52.5 0C. All solutions contained 10 mg/mL aCgn and were prepared
in a 20 mM sodium citrate pH 5 buffer. Figure depicts the Relative Rate Constant (as determined by the
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Figure 5-14: The influence of arginine peptides (in the form of sulfate salts) on aCgn monomer loss due to
aggregation at 52.50C. All solutions contained 10 mg/mL aCgn and were prepared in a 20 mM sodium citrate
pH 5 buffer. Figure depicts the Relative Rate Constant (as determined by the amount of time for 20%
monomer loss) versus additive concentration, with lines drawn through the plots to aid the eye.
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The arginine peptides exhibit a very similar behavior when the chloride ion is replaced
with sulfate. Figure 5-14 shows the improvement in aggregation suppression the sulfate ion
provides over the chloride ion for monomeric arginine. Each additional arginine residue added
improves the aggregation suppression, which is opposite of the behavior exhibited by the
chloride salt forms. The largest peptide tested in this manner was a tetramer, which has a relative
rate constant profile close to that of the generation 0 dendrimer (sulfate salt). If this trend
continues, the larger peptides will likely exceed the performance of the dendrimers.
Even though the larger dendrimers and peptides perform better at inhibiting aggregation,
they might not be optimal for use as a formulation excipient due to tonicity constraints (and
possibly viscosity and toxicological constraints as well). Ideally, protein formulations must be
isotonic (i.e. same osmotic pressure as blood) to minimize pain upon injection. Electrolyte
solutions have a higher osmotic pressure than non-electrolyte solutions due to the presence of
dissociated species. The larger excipients have many counterions per molecule, resulting in a
very high osmotic pressure. Figure 5-15 compares all of the excipients tested at isotonic
concentrations. The figure shows the Shelf Life Extension Factor (i.e. the factor by which the
shelf life of the protein is extended when in the presence of that excipient) for aCgn aggregation.
When compared to sucrose and ArgHCl, all of the excipients developed show improvement in
the shelf life of the protein. However, for both the dendrimers and peptides, the isotonic
concentration for the larger forms is quite low. So low, in fact, that the performance at such
concentrations is less than the performance of the smaller excipients (that is when the smaller
excipients are formulated at isotonic concentrations as well).
As shown in the figure below, the most ideal excipients for formulations seem to be
arginine dimers and generation 0 dendrimers, while the other excipients may be useful during
production and purification steps. A possible way to improve upon the results presented here
might be to introduce other residues into the peptide structure which will increase the size but at
the same time not change the tonicity. Such a design plan was initiated but not followed through
with because the peptides could not be lyophilized successfully. Alternate ways of preparing
such excipients would have to be explored. Furthermore, using a larger core dendrimer or
synthesizing the dendrimers from scratch (possibly using solid phase synthesis techniques) could
allow for larger dendrimers with the same number of surface groups, thus improving aggregation
suppression without increasing the tonicity.
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Figure 5-15: Shelf Life Extension Factor for bovine a-Chymotrypsinogen aggregation (10 mg/mL, T = 52.5*C,
Buffer = 20 mM Na-Citrate, pH 5) at isotonic concentrations for the novel excipients and commonly used
excipients.
5.3. Other Aggregation Conditions
5.3.1. Lower Temperatures
All of the results presented thus far have been for experiments conducted at elevated
temperatures. It was predicted that "neutral crowders" would work at all temperatures, but to
prove that, lower temperature experiments were conducted. Figure 5-16 depicts aCgn monomer
loss with time when incubated at 37*C in the presence of GO dendrimers formulated at isotonic
concentrations. The relative profiles are almost identical to higher temperature data. With no.
excipient present, 5% of the monomer is lost due to aggregation in about a half a day. When in
the presence of an isotonic solution of ArgHCl, a 5% loss occurs after about two days (roughly 4
times longer). However, when in the presence of an isotonic solution of G0-H2PO4 (the
generation 0, guanidinium modified PAMAM dendrimer with a phosphate, monobasic
counterion), this is extended to about 9 days (18 times longer) and when in the presence of an
isotonic solution of GO-SO4, a 5% loss occurs after 25 days (50 times longer).
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Figure 5-16: The influence of GO dendrimer salts on aCgn monomer loss due to aggregation at 37*C. All
solutions contained 10 mg/mL aCgn and were prepared in a 20 mM sodium citrate pH 5 buffer. Figure
depicts monomer concentration, C, normalized with respect to the initial monomer concentration, Co, versus
time, with plots fitted to a second order rate law.
The above figure only represents data collected at one protein concentration and at one
temperature. Table 5-4 depicts k/ko values for a variety of temperatures and two different protein
concentrations. The excipients perform best at low temperatures. However, they also perform
best at lower protein concentrations. Both of these results are not surprising given that protein
solutions are least aggregation prone at low temperatures and at low concentrations. However, at
higher protein concentrations, the aggregation rate reduction is still quite significant and the
novel excipients still outperform ArgHCl by an order of magnitude.
Table 5-4: Relative rate of bovine a-Chymotrypsinogen (aCgn) aggregation at various temperatures and
protein concentrations in the presence of the novel excipients at isotonic concentrations.
10 mg/mL aCgn 40 mg/mL aCgn
37 *C 45 *C 52.5 "C 37 C 45 *C
GO-H 2P0 4 (79 mM) 0.049 0.061 0.053 0.059 0.066
GO-SO 4 (138 mM) 0.02 0.025 0.037 0.0271 0.018
ArgHCI (170 mM) 0.237 0.27 0.303 0.217 0.36
Table 5-5 gives an overview of the average shelf life of aCgn at different temperatures
under three different formulation scenarios. It should be noted that the 250C data are predicted
values using an Arrhenius Plot of low temperature data (37*C - 42.50C). With no additive, the
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shelf life (i.e. the amount of time required for a 5% loss of the monomer) of aCgn ranges from 2
minutes (52.5*C) to only 3.4 days (room temperature). When in the presence of ArgHCl, these
time periods are quadrupled, allowing for a 12 day shelf life at room temperature. But when in
the presences of the GO-SO 4 dendrimer (k/ko = 0.025), the shelf life is increased by a factor of
40, allowing for a shelf life of 5 months at room temperature (which exemplifies the necessity
for performing experiments at elevated temperatures due to this long time frame for a single
experiment). At refrigerated conditions, this could be extended to a much longer period of time,
possibly allowing for a protein that is only stable for a few days to be stored for the time frame
desired (18-24 months).
These results validate the use of high temperature data to analyze excipients. Though, it is
almost impossible to obtain an accurate prediction of shelf life values from high temperature data
due to non-Arrhenius behavior, it does seem that the relative rate constant values remain near
constant over a wide range of temperatures for these excipients. Therefore, if one knows the
shelf life of a protein at low temperature, they can predict the extended shelf life resulting from
the addition of an excipient using high temperature data. These results also show that the
excipients will be of use as formulation excipients. However, additional considerations must be
taken into account (e.g. testing on other proteins, toxicological effects, rates of other degradation
pathways, etc.).
Table 5-5: Time period for a 5% loss of a-Chymotrypsinogen monomer due to aggregation at various
temperatures and rate reductions (10 mg/mL, Buffer = 20 mM Na-Citrate, pH 5).
t9 5 : 5% u-Chymotrypsinogen A Monomer Loss
ArginineDendrimerT (0 Q) No Additive Arginine edirT_(_C) NoAdditive_ k/k 0 = 0.25 k/k 0 = 0.025
52.5 2 Minutes 8 Minutes 1.3 Hours
45 2.1 Hours 8.4 Hours 3.5 Days
37 8.6 Hours 1.4 Days 14 Days
25* 3.4 Days 12 Days 5 Months
10 mg/mL aCgn, 20 mM Sodium Citrate, pH 5
*Predicted Value (Arrhenius Plot of Low Temperature Data)
5.3.2. Other Proteins
The main focus throughout this project has been to develop excipients which will
stabilize therapeutic proteins. However, there is a great need to stabilize proteins for diagnostic
and clinical uses, as well as for research purposes. There are many types of proteins used for
100
Chapter 5 - Novel Excipient Development
such applications, however, one type that is commonly used are lectins, which are a class of
proteins that bind to sugars. Lectins are important in medicine, medical research, biotech
research, biomanufacturing, and recently have been the focus for therapeutic use. But more
importantly, they are commonly used as a diagnostic agent [112]. The most commonly used
lectin is Concanavalin A (Con A), which has seen wide spread use in lectin affinity
chromatography, which is commonly used to purify glycoproteins.
At a pH greater than 7, the predominant form of Con A is a tetramer, but below pH 7 it is
a dimer and is often utilized in this pH range. Furthermore, at a pH below 7, the protein is
unstable, showing a significant amount of aggregation and precipitation at room temperature
within just a few hours. Figure 5-17 shows the Shelf Life Extension Factor for the novel
excipients (as well as several commonly used excipients). Con A was incubated at 37'C at a pH
of 6.5 and the excipients were at or below isotonic concentrations. From these results, it seems as
though Con A is sensitive to ionic strength at such a pH because sodium chloride, sodium
phosphate, and arginine hydrochloride all speed up aggregation. Furthermore, the phosphate
form of the novel excipients shows only a marginal stabilization. The GO phosphate dendrimer
exhibits a Shelf Life Extension Factor of 1.5, which is about the same as that for sucrose and
glycerol. However, the sulfate forms exhibit much improved aggregation suppression. At
isotonic concentrations, the GO sulfate dendrimer extends the shelf life by a factor of 6, while the
GI sulfate dendrimer extends it by 16, showing that for Con A aggregation, the low isotonic
concentrations are not a factor. In addition, it shows the importance of testing all of the salt
forms due to the drastic difference between the phosphate and sulfate forms (this behavior is also
observed for other sodium salts as well).
The most surprising result is the behavior of the arginine peptides. At isotonic
concentrations, the arginine trimer (sulfate salt) extends the shelf life by a factor of 20 while the
arginine tetramer (sulfate salt) extends the shelf life by a factor of 33. This seems to indicate that
larger peptides (as well as larger dendrimers) will perform even better and all of the excipients
will likely be of use at very low concentrations. These are the kind of results desired and
hopefully, such behavior will be observed for other proteins.
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Figure 5-17: Shelf Life Extension Factor for Concanavalin A (7.5 mg/mL, T = 37*C, Buffer = 40 mM Na-
Phosphate, pH 6.5) at isotonic concentrations for the novel excipients and commonly used excipients.
5.4. Thermodynamic Analysis
5.4.1. Preferential Interaction Coefficient
The preferential interaction coefficient for the novel excipients were analyzed to give
insight into how they interact with proteins and influence aggregation. Figure 5-18 depicts the
interaction between the diguanidinium compounds (chloride salt forms) and aCgn. Figure 5-18a
shows F,3 values versus concentration. The error bars have been left off for clarity and lines
have been drawn through the data to aid the eye. The data confirms the hypothesis that there is a
strong interaction between the excipients and the protein. There is also a clear trend between the
magnitude of the attractive interaction and the size of the diguanidinium compound, which is
best represented in Figure 5-18b. In that figure, TP3 values at a concentration of 0.5 M are shown
versus carbon chain length. The F,3 value for guanidinium chloride represents the value at a
carbon chain length of 0. Initially, when the size of the molecule is increased, the attraction
decreases, most likely due to larger volume exclusion. However, as the size continues to
increase, the attractive interaction increases. As mentioned before, the best hypothesis for this
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Figure 5-18: Preferential interaction coefficient values for the interaction between the 1n series of
guanidinium compounds and aCgn (pH 5). (A) Preferential interaction coefficient values versus additive
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Figure 5-19: Preferential interaction coefficient values for the interaction of the GO dendrimer salts and
arginine sulfate dimers with aCgn (pH 5). The error bars have been left off for clarity and lines have been
drawn through the data to aid the eye.
Figure 5-19 shows the preferential interaction coefficient values for the GO dendrimer
compounds and the arginine dimer peptides. Only the preferential interaction coefficient of the
arginine dimer was measured. Larger peptides were not analyzed due to a lack of a sufficient
quantity of peptide for such measurements but also due to the near identical behavior amongst
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the peptides and near identical behavior to the diguanidinium compounds (that is in regards to
aggregation suppression). Therefore, it was assumed that the peptides would also exhibit near
identical preferential interaction behavior, thus it was deemed unnecessary to spend the time and
resources measuring the parameter for all of the peptides.
Contrary to earlier predictions, the chloride form for both types of excipients exhibits a
negative preferential interaction for all concentrations for both types of compounds, indicating
that it is excluded from the protein surface. This is likely due to the large size inhibiting the
compounds from fully solvating the local domain. However, as will be discussed below, this
exclusion does not prevent the molecule from binding to the unfolded state and denaturing the
protein, nor does it mean that the cosolute molecules in the local domain are not forming an
attractive interaction with the protein surface. This result only indicates that the concentration of
cosolute in the local domain is less than the concentration in the bulk solution. There is likely an
attractive interaction formed between the local cosolute molecules and the protein. The other salt
forms (phosphate and sulfate) can be considered naturants, even though they exhibit near
identical preferential interaction coefficient values as the chloride form, though those salt forms
are slightly more excluded. As discussed in the section on arginine salts (Chapter 4), the
phosphate and sulfate ions form attractive interactions with the guanidinium functional group,
something the chloride ion does not do, which likely inhibits the compounds from interacting
with the unfolded state.
The key feature to note is that the preferential interaction coefficient for the sulfate and
chloride dendrimer and peptide excipients exhibits a linear trend with respect to concentration.
However, the phosphate dendrimer exhibits a slightly nonlinear trend. The arginine salts exhibit
a nonlinear trend due to Arg-Arg interactions. It is clear that such interactions are not possible
for the peptides, due to the carboxylate functional group being part of the peptide backbone, and
are not possible for the dendrimers either due to the spherical structure of the polymer
compounds, hence the linear trend. However, this does not exclude the possibility of salt bridges
forming when the counterion is sulfate or phosphate, as observed for the arginine salts. Such
conclusion in regards to cluster formation and salt bridges for the novel excipients is supported
by MD simulation results. Preliminary MD results show no clustering but they show salt bridges
for the sulfate and phosphate forms but not the chloride forms.
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5.4.2. DSC
The denaturing midpoint temperature (Tm) of aCgn in the presence of the dendrimer and
peptide compounds was determined via differential scanning calorimetry (DSC). Figure 5-20
depicts the unfolding transition excess heat capacity versus temperature. The figure shows the
difference in the denaturing midpoint temperature (i.e. the temperature at the peak of the curve)
of aCgn when in the presence of the different GO dendrimers. Table 5-6 gives the denaturation
midpoint temperature increments for the different dendrimer and peptide salts, in addition to
ArgHCl, sucrose, and guanidinium chloride for comparison. The GO dendrimer chloride salt
lowers the melting temperature of aCgn at a rate nearly double that of guanidinium chloride,
which indicates that the compound forms a stronger attraction to the unfolded state and is a much
more potent denaturant. The arginine dimer (chloride salt) also lowers the melting temperature,
but to a much lower extent. This is not surprising given that the compound only has two
guanidinium functional groups and stabilizes proteins over a fairly broad concentration range.
But at a concentration of 1 M, the dimer will lower the melting temperature by nearly 1"C, which
is significant and is likely the reason why the compound speeds up aggregation at such
concentrations.
30
- Buffer (20 mM Na-Citrate, pH 5)
- Arginine HCI (0.5 M) ,
25 - - G0-Phosphate (0.1 M)G0-Chloride (0.1 M) 
-
- GO-Sulfate (0.1 M)
~20
45 50 55 60 65 70 75
Temperature (0C)
Figure 5-20: DSC scans of aCgn in the presence of GO dendrimer salts.
Most importantly, the results show that the phosphate and sulfate GO dendrimers and the
sulfate peptides raise the unfolding temperature significantly. The GO dendrimer phosphate salt
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raises the unfolding temperature at a rate of 37.4 0C/M, the GO dendrimer sulfate salt raises it at a
rate of 15.2 0C/M, and the arginine dimer sulfate salt raises it at a rate of 10.4 *C/M (which is
more than that for monomeric ArgH(S0 4)1 2). All values are significantly higher than that for
sucrose (0.7 0C/M), which is a commonly used conformational stabilizer, thus indicating that the
phosphate and sulfate salts of the novel excipients are potent naturants. However, the trends in
the aggregation behavior make it seem that these salt forms also inhibit association as well.
Table 5-6: Denaturing midpoint temperature increments for aCgn in the presence of GO dendrimers, arginine
dimers, and other excipients.











The hypothesis developed for the mechanism behind the arginine salts studied seems to
extend, in part, to the dendrimers and peptide excipients. Phosphate, sulfate, and possibly citrate
form attractive interactions with the guanidinium functional groups through hydrogen and
electrostatic bonding. These interactions should cause the solutes to form salt bridges and inhibit
them from binding to the unfolded state. The large size of the dendrimer and peptide excipients
should cause them to be potent "neutral crowders", even though they are somewhat excluded
from the surface of the protein. This is relative to the exclusion an inert molecule the same size
as the compound should exhibit. If the excipients had no attraction to the proteins surface, their
preferential interaction coefficient values would show them to be more than 4 times as excluded,
making it reasonable to refer to them as "near-neutral" rather than "neutral" or "excluded".
Conformational stabilization further enhances the aggregation suppression (as opposed to the
denaturing effect of the chloride salt, which counteracts any association suppression that is
observed at low concentrations). Moreover, the large size of the excipients and the bridged
network of ions should also increase the viscosity of the solution and inhibit the motion of the
protein molecules, thus causing an increased diffusional barrier to association.
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MD simulations will have to be conducted to give further molecular level insight into the
mechanism of action. However, the importance of the guanidinium functional group can easily
be demonstrated and is illustrated below. Figure 5-21 compares the aggregation suppression
ability of dendrimers with a guanidinium surface to dendrimers with the original ammonium
surface (of course, dendrimers of the same size containing the same counterion were compared).
A PAMAM dendrimer with an ammonium chloride surface has a similar profile to that of the
guanidinium chloride surface, however, the relative rate constant for the guanidinium chloride
dendrimer is significantly lower than the ammonium counterpart for all concentrations,
indicating a greater ability for suppressing aggregation. In fact, at low concentrations, the relative
rate constant for the ammonium chloride dendrimer is not much less than unity, indicating
almost no ability for inhibiting aggregation. Furthermore, when the counterion is switched to
phosphate, the ammonium dendrimer switches from an excipient that only marginally stabilizes
proteins at low concentrations to one that inhibits aggregations at all concentrations, like its
guanidinium counterpart (the trend plateaus at higher concentrations as well). However, the
ability of the ammonium phosphate dendrimer to inhibit aggregation is an order of magnitude
less than the guanidinium phosphate dendrimer. Moreover, the same behavior is observed when
arginine is compared to lysine, the closest amino acid analogue to arginine. All of these results
indicate that the guanidinium functional group plays an important role and is an essential feature
in the mechanism of action.
These results support the hypothesis presented above in that the improved aggregation
suppression is a result of the guanidinium functional group forming a strong interaction with the
phosphate, sulfate, and citrate counterions. This can be said because even though the ammonium
functional group can form hydrogen bonds, it cannot form hydrogen bonds with such counterions
in the same manner as guanidinium because of its smaller size and fewer hydrogen bond
donating sites. As a result, the interaction with the counterions is much weaker for ammonium
and salt bridge formation is most likely nonexistent. The reason for the guanidinium chloride
dendrimer being a better aggregation suppressor than the ammonium chloride dendrimer at low
concentrations is most likely due to the stronger attractive interaction the guanidinium dendrimer
forms with proteins. Guanidinium chloride by itself inhibits aggregation at low concentrations
due to it inhibiting protein-protein interactions, which is a result of its interaction with proteins,
while ammonium chloride does not exhibit such behavior because it cannot form as strong of an
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Figure 5-21: The impact the guanidinium surface has on aCgn monomer loss due to aggregation at 52.5*C.
The figure compares dendrimers with a guanidinium surface to a dendrimer with an ammonium surface
(same size and counterion). All solutions contained 10 mg/mL aCgn and were prepared in a 20 mM sodium
citrate pH 5 buffer. Figure depicts the Relative Rate Constant (as determined by the amount of time for 20%
monomer loss) versus additive concentration, with lines drawn through the plots to aid the eye.
A similar inquiry must be made into how much of the observed effect is the result of the
dendrimer and how much is the result of the counterion. This question should be asked because
sulfate and phosphate salts are common protein stabilizers and as shown in the figure above, the
ammonium phosphate dendrimer inhibits aggregation as well. Therefore, the performance of the
dendrimer phosphate and sulfate salts were compared to sodium phosphate and sodium sulfate
(see Figure 5-22). One thing to note is that guanidinium dendrimers have multiple counterions,
therefore, for a fair comparison, the performance of the dendrimers should be compared to the
sodium analogues at a concentration 6 times that of the GO phosphate dendrimer and 3 times that
of the GO sulfate dendrimer. When the relative rate constant for the GO guanidinium phosphate
dendrimer at 0.1 M is compared to sodium phosphate at 0.6 M, it is obvious that the dendrimer
has a significantly lower rate constant (0.04 for the dendrimer and only 0.1 for sodium
phosphate). A similar result is observed for the sulfate salts (a relative rate constant of 0.03 for
the sulfate dendrimer at a concentration of 0.15 M and a value of 0.08 for sodium sulfate at a
concentration of 0.45 M).
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Figure 5-22: The impact the counterion has on aCgn monomer loss due to aggregation at 52.5*C. The figure
compares dendrimer salts with the sodium salts containing the same anion. All solutions contained 10 mg/mL
aCgn and were prepared in a 20 mM sodium citrate pH 5 buffer. Figure depicts the Relative Rate Constant
(as determined by the amount of time for 20% monomer loss) versus additive concentration, with lines drawn
through the plots to aid the eye.
For both types of salts, the guanidinium dendrimer version lowers the relative rate
constant by a factor of 2.5 when compared at the same anion concentration, which indicates the
impact the large molecule has on aggregation suppression. Contrary to this, the GO ammonium
phosphate dendrimer at 0.1 M only has a relative rate constant of 0.2. This indicates that the
ammonium dendrimer has a detrimental effect on protein stability when compared to sodium,
further exemplifying the role of the guanidinium functional group. Furthermore, it should be
noted that sodium sulfate significantly reduces the solubility of the protein at concentrations
above 0.5 M, showing that the dendrimer salts can inhibit aggregation without adversely
affecting the solubility of the protein.
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6.1. Completion of Thesis Goals
As stated in Chapter 1, the main objectives of this thesis project were to:
1. Develop and test a novel class of excipients with the aim of dramatically improving
the stabilization of protein therapeutics against aggregation.
2. Elucidate the mechanism by which arginine and the novel excipients inhibit
aggregation.
As outlined in Chapter 4, a detailed study was conducted that has resulted in more insight
into the mechanism by which arginine inhibits aggregation, in addition to showcasing additional
arginine salts with improved aggregation suppression abilities. Furthermore, Chapter 5 details
the development of a novel class of solutions additives and demonstrates their aggregation
suppression abilities. Furthermore, the chapter includes thermodynamic data and a mechanistic
inquiry, giving insight into the mechanism by which the novel excipients inhibit aggregation.
The next step from here will involve implementing the developed excipients into pharmaceutical
formulations and protein production steps.
6.2. Design Features Explored
In summary, three types of excipients were produced, modified amine compounds,
modified PAMAM dendrimers, and arginine peptides. The modified amine compounds consisted
of diguanidinium compounds and triguanidinium compounds with either two or three alkyl
chains. Generation 0 through generation 2 PAMAM dendrimers were modified, each with an
ethylene diamine core. The peptides consisted of small oligomers ranging in size from a dimer to
a heptamer, most consisting of all arginine residues but some containing other residues such as
glutamic acid and serine. The diguanidinium compounds showed that having a hydrophobic core
is detrimental to the solubility of the solute. Moreover, the diguanidinium compounds
demonstrated a counterintuitive behavior in regards to the larger compounds exhibiting a
stronger rather than weaker interaction with proteins, which causes them to be more
destabilizing. The dendrimers and peptides also exhibited this counterintuitive behavior.
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It was discovered, though, that the key behind producing a stabilizing compounds lay, in
part, with the choice of counterion to the guanidinium functional group. As described above,
placing guanidinium functional groups on the surface of a large molecule to counter the strong
repulsive interaction resulting from a large volume exclusion effect did not produce the results
desired. The attractive interaction between the compounds and the protein were stronger than
expected. However, exchanging the chloride ion with a counterion with a strong hydrogen bond
accepting characteristic reduced this interaction due to a favorable interaction between the
guanidinium functional group and the counterion. A study of different arginine counterions
indicated that such counterions lead to cosolute clustering, which is likely the key to why the
counterions enhance aggregation suppression. This mechanism likely extends to the dendrimer
and peptide excipients.
6.3. Novel Excipients Produced
In summary, there are three types of novel excipients produced:
1. Arginine Salts (e.g. arginine phosphate, arginine sulfate, arginine citrate, etc.)
2. Guanidinium Modified PAMAM Dendrimers (with either a phosphate, sulfate, or
citrate counterion)
3. Arginine Peptides (with either a phosphate, sulfate, or citrate counterion)
6.4. Elucidation ofAggregation Suppression Mechanisms
Early results seemed to indicate that arginine hydrochloride may be a naturally occurring
"neutral crowder" compound. However, a more detailed investigation showed that the
mechanism was more complex since arginine exhibited an unusual preferential interaction
behavior. Furthermore, arginine peptides were shown to be destabilizing, indicating that the
arginine mechanism was not simply a balance of attraction and repulsion with the protein
surface. Rather, the behavior of arginine in solution is as important as how it interacts with the
protein surface. MD simulations indicated that this behavior was likely due to attractive
interactions between arginine molecules, which cause arginine molecules to form clusters in
solution, something the arginine peptides could not do. Furthermore, an investigation into other
counterions showed that attractive cation-anion interactions in solution lead to the formation of
even larger and more extensive clusters. This effective size enhancement of the molecules
around the protein inhibits arginine from binding too strongly with the protein surface and
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increases the "Gap effect", which enhances the inhibition of protein-protein association.
Furthermore, cluster formation likely leads to an increase in the viscosity of the solution, thus
lowering the diffusion of proteins in solution. Therefore, arginine affects the rate of aggregation
via three mechanisms: 1) enhancing the native state conformational stability (only for phosphate,
sulfate, and citrate salts), 2) increasing the barrier for protein-protein association (both for
individual arginine molecules and arginine clusters) and 3) increasing the viscosity of the
solution medium.
The novel excipients should also exhibit a similar mechanism due to their similarity with
arginine. The dendrimers and peptides cannot self associate like individual arginine molecules
due to their large and complex structure. Therefore, they tend to interact strongly with the
surface of the protein, rather than with other cosolute molecules in the bulk solution. However,
when the counterion is phosphate, sulfate, or citrate, the novel excipients should form salt
bridges in solution due to the interaction between guanidinium and those counterions. This
clustering reduces the interaction with the protein surface, eliminating and reversing the
conformation destabilization induced by the compounds, and enhancing protein association
inhibition.
In conclusion, neither arginine nor the novel excipients are simple "neutral crowder"
compounds. A simple "neutral crowder" compound likely cannot be created by balancing
attraction with volume exclusion due to an unexpected cooperative interaction with the protein
surface.
6.5. Significance of Results
The arginine salts and novel excipients exhibit an aggregation suppression ability that is
greater than commonly used excipients. At isotonic concentrations, the arginine salts allow for a
shelf life that is more than double that for solutions containing ArgHCl. Moreover, the peptides
can quadruple the shelf life when compared to ArgHCl and the dendrimers can extend the shelf
life even further, by a factor of 8. With aggregation suppression an order of a magnitude greater
than commonly used excipients, the novel excipients should be useful for reducing the
aggregation of diagnostic and therapeutic proteins in many different applications, such as in
formulations, production, purification, clinical use, and research. Furthermore, the mechanistic
inquiry into the mechanism of action of arginine and the novel excipients reveals a lot about how
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The main objective during this study was to develop an excipient which inhibits the
aggregation of a model protein under accelerated conditions. This and only this was considered
due to the large amount of work involved in synthesizing and assessing a novel class of
excipients. Even though this objective was met, there are a lot of other factors that need to be
considered before the excipients can be utilized. These include but are not limited to
determining:
1. Whether or not the excipients are toxic and determining if they can be included in a
formulation if found to be nontoxic.
2. Whether or not the novel excipient inhibit the aggregation of other proteins
(therapeutic and diagnostic proteins in particular).
a. Do the excipients work universally?
b. If not, which type of proteins do they work best on?
c. What is the mechanism for this if that is the case?
d. Can the formulation conditions be tuned for them to work universally?
3. Whether or not they truly inhibit aggregation at room or refrigerated temperatures.
4. How the excipients influence the maximum concentration of a protein. For example:
a. Do they diminish it because of their size?
b. Will they help to increase the maximum concentration due to slower
aggregation?
5. Whether or not the excipients cause the viscosity to be too high for them to be
utilized.
6. The optimal pH range and formulation conditions, in addition to compatibility with
other commonly used excipients.
7. Whether or not the novel excipients inhibit the aggregation caused by other stresses
(e.g. shaking and shearing, freezing and thawing, dialysis, ultrafiltration, refolding,
etc.).
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8. How well they inhibit aggregation during protein production steps.
9. How the excipients influence other degradation pathways (e.g. deamidation,
oxidation, etc.).
10. Whether or not the purity of the excipients needs to be higher (e.g. the impurities
might be toxic or detrimental to the long term stability of proteins).
11. Whether or not the excipients themselves remain stable over time.
12. How easily the excipients can be removed from a solution if found to be not
applicable for formulations but are utilized elsewhere during production and
purification.
7.2. Improved Excipients
Now that a group of working excipients has been developed and the mechanism by which
they inhibit aggregation somewhat elucidated, it is clear that there are many other variations that
can be explored to further improve aggregation suppression performance.
7.2.1. Higher Purity
The purity of the dendrimer excipients is somewhat low (<80%) due to residual solvents.
This remains to be the case even when the dendrimers are dried over a longer period of time. It
was apparent after the ion exchange experiments that simply dissolving the chloride form of the
dendrimer excipients in water and evaporating away the water via lyophilization that much of the
residual solvent is removed and this resulted in an improved performance of the chloride form.
Therefore, it is probably best to purify the dendrimer excipients via a more robust method (e.g.
HPLC, dialysis, etc.) to obtain the excipients in the highest purity possible and to eliminate any
undesirable impurities. This will likely improve the performance of the sulfate and phosphate
form of the dendrimer excipients (even though they should already be more pure than the
original chloride form they were produced from).
7.2.2. Synthesizing PAMAM Dendrimers from Scratch
As discussed earlier, one major drawback of the excipients developed is their high
tonicity resulting from many counterions per molecule. It might be beneficial to make the
excipients larger while keeping the number of functional groups on the surface the same. One
could simply utilize the commercially available PAMAM dendrimers with larger cores, however,
that could be detrimental to the smaller dendrimers due to an increase in the hydrophobic
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character of the core structure, which is more exposed to the solvent in the smaller generations.
Moreover, the smaller generations are likely to be the most optimal due to a higher isotonic
concentration and lower toxicity, making it even less desirable to use the dendrimers with a
larger core.
Even though they might not give beneficial results, the larger core dendrimers should still
be explored to gain more insight into the most optimal structure. However, if one wants to make
the dendrimers larger by making the branches longer, the dendrimers will have to be synthesized
and purified from scratch. The commercially available PAMAM dendrimers have alkyl chains
two carbons long on either side of the amide functional group because the reactants utilized to
make the branches (methyl acrylate and ethylene diamine) are used specifically for their
volatility (i.e. after the synthesis step, the reactants are easily removed via simple evaporation).
To make longer branches, reactants with longer alkyl chains will have to be utilized. However,
such reagents will become less and less volatile, thus a different synthesis/purification method
will have to be utilized. It might be possible to synthesize the dendrimers via a solid phase
synthesis technique, growing the dendrimers on a polymer substrate and washing away the
reactants after each step rather than evaporating them. After the synthesis, the dendrimers can be
cleaved from the addition of an acid. Furthermore, the surface of the dendrimers can be modified
prior to cleavage, making the synthesis and purification less cumbersome on top of producing a
product with a much higher purity without the use of a purification step. However, the synthesis
of larger dendrimers might be troublesome due to an increased likelihood of crosslinking nearby
branches, which is another reason why only smaller reactants are utilized.
7.2.3. Incorporating Other Amino Acids
The arginine peptides are a much more attractive group of excipients to work with in
regards to making larger excipients with the same number of functional groups because the
method to do so is quite simple. All one has to do is introduce other residues into the sequence
which are hydrophilic but at the same time not electrolytic (e.g. serine). The structures that can
be produced are essentially limitless, thus many different design features can be explored,
allowing for the behavior of the excipient to be fine tuned. It might even be possible to tune the
excipient on a case by case basis to obtain the maximum aggregation suppression possible.
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7.2.4. Surface Modified to Urea
The other protein binding functional group that can possibly be utilized in the same
manner as guanidinium is urea. Therefore it might be possible to modify the surface of the
excipients to urea (including using lysine peptides as a starting material). However, urea has no
counterion, thus the behavior of such compounds cannot be influenced by introducing a different
counterion. But this might not be necessary because urea does not bind to proteins as strongly as
guanidinium. If a urea modified excipient is found to inhibit aggregation, it will be beneficial
because it can be utilized at higher concentrations due to a much lower tonicity resulting from a
lack of counterions (that is if such compounds are soluble, which might be an issue if urea is the
surface group). Furthermore, they will likely be less toxic since they will not have a positively
charged surface. Large molecules with a positively charged surface have been shown to be toxic
to cell lines and detrimental to red blood cells. Neutral and negatively charged compounds do not
exhibit this behavior [113].
7.3. Applications
7.3.1. Formulation
Throughout this project, the main goal has been to develop new excipients for use in
formulations. However, as outlined above, it will not be a straightforward or a quick process for
the novel excipients to be implemented as formulation additives. There are many things to
consider, with the toxicological effects at the top of the list. If the excipients pass all of the
considerations outlined above, they will likely be of use in therapeutic and diagnostic
formulations.
7.3.2. Production & Purification
A more immediate and possibly greater use for the excipients might be as additives
during production and purification. Several of the steps involved during the production and
purification of proteins are detrimental to the structure of the protein and can cause rapid
aggregation. This aggregation can greatly reduce the yield of a costly product and places a huge
burden on downstream purification steps. One example of this is Protein A affinity
chromatography, which is often the first purification step in the production of antibodies.
Antibodies bind to the column when dissolved at a moderate pH and are eluted by lowering the
pH to around 2-3. This extreme pH is detrimental to the protein structure and causes significant
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aggregation [114]. The novel excipients inhibit protein-protein interactions and might be of use
eluting the antibodies at a higher and less detrimental pH, similar to the effect arginine has on
Protein A elution. Furthermore, they will help to reduce the aggregation that occurs during
elution and the virus hold step. Other production and purifications steps may include
fermentation, refolding, affinity chromatography, etc. Furthermore, ionic exchange and size
exclusion chromatography steps are often utilized during the polishing steps, which can be
utilized to remove the excipients from the solution if they are not desired or cannot be used in the
final formulation recipe.
7.4. Toxicological Study
As mentioned before, large molecules with a positively charged surface have been shown
to be toxic to cell lines and detrimental to red blood cells. Therefore, the guanidinium modified
compounds might be too toxic to be used as a formulation additive. Furthermore, small peptides
can cause allergic reactions, making an immunogenic and toxicological study absolutely
essential. Even though PAMAM dendrimers have received a tremendous amount of attention in
regards to therapeutic uses, only a relatively small amount of research has been devoted to
determining their toxicological effects, likely due to the high cost of such studies [113]. The
research that has been conducted has shown an in vitro toxic effect that is generation dependent.
The larger PAMAM dendrimers are more toxic, while the smaller generations seem promising
for therapeutic use. in vivo studies with mice show no detrimental effect in regards to the life
span or behavior of the mice, except for the very large generation 7 PAMAM dendrimer.
Furthermore, the dendrimers showed no immunological effects, which is a positive sign. Similar
and more rigorous studies will have to be conducted for the modified dendrimers before anyone
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Appendix A - NMR & MS Data
Modified Di- and Tri-Amine Compounds
NMR and MS data were not collected for any of the modified amine compounds. There
was high certainty in the complete conversion to guanidinium for these compounds and in the
purity of the resulting products due to the simplicity of the reaction and the effective separation
via TLC. Due to the cost and labor required to collect the structural data, it was deemed prudent
to test the synthesized compounds first and only collect structural data if results were to be
published. The excipients synthesized from the amine compounds were found to be destabilizing
due to a strong preferential interaction and the conversion to other guanidinium salts to reduce
this interaction failed due to low solubility. Thus, further development with such compounds was
not explored due to this and the success of the dendrimer and peptide compounds.
BOC Protected Guanidine Modified PAMAM Dendrimers
Generation 0 (GO-BOC)
(4CN[CH2]C2*OIH hCH2NHiC(NHICOOC(CH)3)(kNlCOOMC(II'CH3)3)]2)2[(CH2fCH2 ]-~g~N C
Purity (NMR): 91.4 %
'H-NMR (400 MHz, CDCl3): 8 ppm 11.40 (4H, s, k), 8.51 (4H, t, J=5.5 Hz, i), 7.94 (4H, t, J=4.7
Hz, f), 3.50 (8H, q, J=5.7 Hz, h), 3.34 (8H, q, J=5.6 Hz, g), 2.61 (8H, t, J=5.5 Hz, c), 2.35 (4H, s,
a), 2.29 (8H, t, J=5.6 Hz, d), 1.433 (36H, s, n'), 1.439 (36H, s, n)
13C-NMR (101 MHz, CDCl 3): 6 ppm 173.3 (e), 163.4 (j), 157.0 (E), 153.1 (1), 83.4 (M), 79.5
(m'), 52.2 (a), 50.5 (c), 40.6 (h), 39.8 (g), 34.3 (d), 28.2 (n'), 28.5 (n)
MS (ESI*): m/z calculated for C6 6H12 0NI8 0 20 [M+H]*: 1485.90; found: 1485.91 (100%):
[M+2H-COOC(CH 3)3]*: 1385.85; found: 1385.86 (43%), [M+Na]*: 1507.88; found: 1507.89
(38%).
Generation 1 (G1-BOC)
[CH2 CH2]-[-N(-CH 2--CH2 -CO-NH1CH 21 CH 2 2N[2CH2ACH 2eCOfNHNCH 2 CH 21NHiC(kNHICOOnC
(fCH3)3)(LNlCOOmnC(&'CH 3)3)]2)2] 2
Purity (NMR): 90.6 %
'H-NMR (400 MHz, CDCl 3): 6 ppm 11.37 (8H, s, k), 8.51 (8H, t, J=5.5 Hz, i), 7.95 (8H, t, J=5.3
Hz, 2), 7.69 (4H, t, J=5.4 Hz, fl), 3.49 (16H, q, J=5.6 Hz, h2), 3.33 (16H, q, J=5.4 Hz, g2), 3.18
(8H, q, J=5.7 Hz, gl), 2.65-2.72 (24H, br t, cl+c2), 2.49 (8H, t, J=5.7 Hz, hi), 2.45 (4H, s, a),
2.28-2.31 (24H, br t, dLd2), 1.43 (72H, s, n'), 1.42 (72H, s, n)
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13 C-NMR (101 MHz, CDCl 3): 8 ppm 172.8-173.0 (el+e2), 163.3 (j), 157.0 (1'), 153.1 (1), 83.4
(m), 79.4 (m'), 52.3-52.5 (a+hl), 50.4-50.5 (c1+c2), 40.6 (h2), 40.0 (g2), 37.6 (gi), 34.1-34.2
(dl+d2), 28.2 (n'), 28.5 (n)
MS (ESI*): m/z calculated for C1 5oH2 72N4 2 O44 [M+2H]2+: 1684.02; found: 1684.54 (100%),
[M+3H-COOC(CH 3)3] 3*: 1633.99; found: 1634.52 (97%), [M+Na]*: 1695.51; found: 1695.53
(53%).
Generation 2 C 2G2-BOC hi b
[ CH24CH2]-(L-N[ lCH2-CH2-COnNHg'CH2 'CH2 2N( 92CH2L2CH2 2CO2NH92CH2haCH2
LN[ 3CH2d!CH2 13COfNHg3CH2 h3CH2 !NHJC( NHICOOmC(nCH3)3)(LNI COOM'C(liCH3)3)]2)2]2)2
Purity (NMR): 94.9 %
iH-NMR (400 MHz, CDCl3): 6 ppm 11.37 (16H, s, k), 8.51 (16H, t, poorly resolved, i), 7.96
(16H, t, poorly resolved, f), 7.82 (4H, t, poorly resolved, fl), 7.64 (8H, t, poorly resolved, f2),
3.49 (32H, q, J=4.9 Hz, h3), 3.33 (32H, q, J=4.3 Hz, g3), 3.18-3.21 (24H, br t, gI+g2), 2.65-2.72
(56H, br t, c1c2+c3), 2.45-2.49 (28H, br m, a+hl+h2), 2.25-2.32 (56H, br t, dl+d2+d3), 1.424
(144H, s, n'), 1.418 (144H, s, n)
13C-NMR (101 MHz, CDCl 3): 6 ppm 172.9-173.1 (eel+2+e3), 163.3 (i), 157.0 ('), 153.0 (1),
83.3 (in), 79.4 (m'), 52.4-52.6 (hi), 50.3-50.4 (cl+c2+c3), 40.6 (3), 40.0 (g3), 37.5-37.6
(gl+g2), 34.1-34.2 (d1+d2+d3), 28.2 (n'), 28.5 (n)
MS (ESI*): m/z calculated for C3 18H5 7 6N9 00 9 2 [M+20H] 20+: 357.42; found: 357.22 (100%)
Guanidine HCI Modified PAMAM Dendrimers
Generation 0 (GO-Gdn)
[gCH2CH2]-(NH[*CH2 CH2gCOfNHgCH2hCH2!NHiC(kNH2)2]2)2
Purity (NMR): 77.0 %
Yield: 81.8 %
1H-NMR (400 MHz, DMSO-d 6): 6 ppm 11.06 (2H, br s, b), 8.50 (4H, t, J=5.1 Hz, i), 7.89 (4H, t,
J=5.2 Hz, f), 7.34 (16H, br s, k), 3.72 (4H, br s, a), 3.43 (8H, t, J=6.3 Hz, c), 3.20-3.24 (16H, br
m, g+h), 2.77 (8H, t, J=6.9 Hz, d)
13C-NMR (101 MHz, DMSO-d6): 6 ppm 169.3 (e), 157.3 (), 49.2 (c), 46.4 (a), 40.1 (g), 38.0 (h),
29.3 (d)
MS (ESI*): m/z calculated for C2 6H62Ni 8 0 4Cl6 [M-6HCl+2H] 2+: 343.24; found: 343.25 (100%);
[M-6HCl+3H] 3+: 229.17; found: 229.17 (59%), [M-6HCl+4H] 4*: 172.13; found: 172.13 (16%),
[M-6HCl+H]*: 685.48; found: 685.51 (4%).
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Generation 1 (G1-Gdn)
[ACH 2ACH 2]-
[ -NH( 'CH24-'CH2g-'CORNH&'CH2b-CH2 2NH[ 2CH24CH2g2CO1NHaCH2b2CH2-'NHiC( NH2)2]2)
2]2
Purity (NMR): 70.4 %
Yield: 78.5 %
'H-NMR (400 MHz, DMSO-d6): 6 ppm 11.09 (2H, br s, hi), 10.45 (4H, br s, h2), 8.67 (4H, t,
poorly resolved, fl), 8.51 (8H, t, poorly resolved, i), 7.91 (8H, t, poorly resolved, f2), 7.36 (32H,
br s, k), 3.73 (4H, br s, a), 3.45-3.53 (8H, br q, gl), 3.35-3.45 (24H, br t, c1+c2), 3.18-3.27 (40H,
br m, hh2+g2), 2.71-2.85 (24H, br t, dl+d2)
"C-NMR (101 MHz, DMSO-d6 ): 6 ppm 169.5-169.6 (e1+e_2), 157.3 (1), 51.3 (h), 48.7-48.8
(+c2), 46.5 (a), 40.2 (g2), 38.1 (h2), 33.7 (gi), 29.1-29.3 (i+d2)
MS (ESI*): m/z calculated for C7oH1 58N420 1 2Cli 4 [M-14HCl+6H]6+: 295.21; found: 295.21
(100%), [M-14HCl+5H] 5*: 354.05; found: 354.06 (90%), [M-14HCl+4H] 4*: 442.31; found:







H-NMR (400 MHz, DMSO-d6): 6 ppm 11.09 (2H, br s, hi), 10.40-10.44 (12H, br s, h2+h3),
8.62-8.69 (12H, br t, f+t2), 8.51 (16H, t, poorly resolved, i), 7.91 (16H, br t, poorly resolved,
_), 7.34 (64H, br s, k), 3.65-3.75 (20H, br m, ah2), 3.48-3.53 (24H, br q, g1+g2), 3.35-3.48
(56H, br t, cl+c2+c3), 3.18-3.27 (72H, br m, h+1h+g3), 2.71-2.82 (56H, br t, d1+d2+d3)
"C-NMR (101 MHz, DMSO-d6): 6 ppm 169.5-169.7 (el+e2+), 157.3 (j), 51.3-51.4 (hL+h2),
48.7-48.8 (d+c2+c3), 46.6 (a), 40.2 (ga), 38.1 (h3), 33.7-33.8 (g1+g2), 29.1-29.3 (dL+d2+d3)
MS (ESI*): m/z calculated for C158H35oN9 00 28CI30 [M-29HC1 1H]"+: 361.25; found: 361.26
(100%); [M-30HCl+8H]8 +: 492.11; found: 492.11 (97%), [M-30HCl+9H] 9*: 437.54; found:
437.54 (92%), [M-30HCl+10H]': 393.89; found: 393.88 (47%), [M-30HCl+7H] 7*: 562.27;




MS (ESI+): m/z calculated for RR [M+2H]2+: 166.20; found 166.10 (100%), [M+H]*: 331.39;
found 331.15 (30%).
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Arginine Dimer (RS)
HPLC Purity: 99.3%
MS (ESI*): m/z calculated
Arginine Dimer (RL)
HPLC Purity: 99.1%
MS (ESI*): m/z calculated
Arginine Dimer (RQ)
HPLC Purity: 99.7%
MS (ESI*): m/z calculated
Arginine Dimer (RE)
HPLC Purity: 99.1%
MS (ESI*): m/z calculated
Arginine Trimer (RRR)
HPLC Purity: 98.2%
for RS [M+H]*: 262.28; found 262.10 (100%).
for RL [M+H]*: 288.36; found 288.15 (100%).
for RQ [M+H]*: 303.34; found 303.10 (100%).
for RQ [M+H]*: 304.34; found 304.15 (100%).
MS (ESI*): m/z calculated for RRR [M+2H]2+: 243.79; found 244.25
163.19; found 163.10 (52%), [M+H]*: 487.57; found 487.30 (18%).
Arginine Trimer (RER)
HPLC Purity: 99.1%








MS (ESI*): m/z calculated for RRRR [M+2H]2+: 322.38; found 322.35 (100%), [M+3H] 3*:
215.25; found 215.20 (96%), [M+H]*: 643.76; found 643.35 (13%).
Arginine Tetramer (RREE)
HPLC Purity: 98.0%








(100%) , [M+H]*: 460.50;
00%), [M+2H]2+: 217.22;
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Table B-1: Summary of solute partial molar volume and dependence of solution osmolality on solute
molality for two-component solutions
cosolute partial molar volume C23"(2) (pH 6.0)a 30( (pH 3 .5 )b range (m )
(comp. 3) (L/mol) x 102 mol/kg
argHCl (14.21 ± 0.01) + (1.716 0.001) - (1.678 0.001) - M3<0.70
(0.22 ±0.01)m3  (0.674 0.004) 3  (0.542 0.002) 3
gdnHCl (6.94 0.01) + (1.795 ± 0.01)- (1.747± 0.001) - M3<0.76
(0.048 0.003)m 3  (0.598 ± 0.002 3  (0.4906 ± 0.002) 3
glucose (11.192 ±0.003)+ 1.016+0.001 1.01310.001 M3<1.20
(0.044 ± 0.003)m 3
glycerol (7.118 0.003) - 0.9956 ± 0.0005 0.974 0.001 M3<1.14
(0.030 + 0.00 l)m 3
urea (4.452 0.002) - (0.9744 0.0005) - (0.916 0.001) - M3<1.22
(0. 117 ± 0.003)n 3  (0.0918 0001 3  (0.008 00.001 3
protein partial molar volume Q 203 (pH 6.0)a Q 2(' (pH 3 .5 )b range (in)
((comp. 2) (L/mol) mmol/kg
BSA 47.731 ± 0.001 3.6± 0.9 N/A 10902M2 2.1
lysozyme 10.005+± 0.001 3.2± 0.9 N/A 3.5M 2 <3.8
aCgn 17.910±L0.001 N/A 4.4±0.8 1.65. 0 01.75
a The base buffer was 40 mM Na-Phosphate; b The base buffer was 20 mMv Na-Citrate.
Table B-2: Summary of preferential interaction coefficients for BSA as
literature values








glycerol (1.014 ± 0.001) -
(0.0012± 0.001)m 3




(1.7 * 3.9)M3 -

























(13.0 1 .2 )[ 3 ]b
(-19.8 0.9)[3]C
It should be noted that [3] represents the molar concentration of the cosolute. The base buffer was 40 mM Na-
Phosphate, pH 6.0 and BSA concentration held constant at 1.8 mM. The values represented are an average of the
separate approximations computed by Eqs. (3.15) and (3.18). a Calculated from data in Reference [85]. b Calculated
from data in Reference [33]. C Calculated from data in Reference [32]. d Calculated from data in Reference [115].
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(1.670 ± 0.001) -
(0.560 0.004)m3
gdnHCl (1.770 0.001) -
(0.584 0.002)m3
glucose (1.026 ± 0.001) -
(0.001 0.002)m3
glycerol (1.018 0.001) -
(0.002 0.002)m 3
urea (0.962 0.001) -
(0.090 0.002)m 3
T,.1
(-1.9 ± 0.3) ±
(5.2 2.2)m3 -(6.5 3.3)m 32
(-2.0 0.3) +
(2.9 0.6)m3
(-2.8 ± 0.3) -
(2.4 0.5)m 3
(-2.2 ± 0.3) -
(5.7 0.5)m 3
(-4.3 0.3) +
(2 .7 0.3)m 3



















It should be noted that [3] represents the molar concentration of the cosolute. The base buffer
Phosphate, pH 6.0 and lysozyme concentration held constant at 3.5 mM. The values represented are
separate approximations computed by Eqs. (3.15) and (3.18). a Calculated from data in Reference [85].
data in Reference [34].
Table B-4: Summary of preferential interaction coefficients for a-
Chymotrypsinogen A as measured by VPO
was 40 mM Na-
an average of the
b Calculated from
cosolute 23
argHCl (1.676 ± 0.001) -
(0.514 0.004)m 3
gdnHCl (1.736 0.001) -
(0.488 0.002)m 3
glucose (1.022 0.001) -
(0.001 0.002)m 3
glycerol (0.999± 0.001) -
(0.002 0.002)m 3
urea (0.902 0.001) -
(0.015 0.001)m 3
Ip1
(-2.8 ± 0.8) +
(0.2 5.8)m3 -(6.6 ± 8.1)m 32
(-0.8 ± 0.6) ±
(4.1 ± 1.1)m 3
(-4.5 ± 1.2) -
(5.1 ± 0.8)m 3








(0.5 ± 0.7)[3] -
(10.4 2.5)[3]2





(9.4± 1)[3] (9.1 ± 1)[3]
136
It should be noted that [3] represents the molar concentration of the cosolute. The
base buffer was 20 mM Na-Citrate, pH 3.5 and aCgn concentration held constant at 1.7
mM. The values represented are an average of the separate approximations computed
by Eqs. (3.15) and (3.18).
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Table B-5: Preferential interaction coefficients for





0.47 0.708 ± 0.002 0.713 ± 0.001 (-5.2 2.8)
0.87 0.717 ± 0.002 0.734 ± 0.002 (-21.3 4.3)
lysozyme, pH 6.0
0.38 0.713 ± 0.002 0.706 ± 0.002 (1.6 0.7)
0.87 0.697 ± 0.002 0.710 ± 0.002 (-3.4 0.8)
The base buffer was 40 mM sodium phosphate, pH 6.0.
Table B-6: Summary of VPO preferential interaction coefficient data, aCgn denaturation midpoint
temperature increments, cosolute partial molar volume (PMV), and Pitzer ion interaction parameters for
arginine salts and guanidinium chloride.
Salt Fu3  dTm/d[31 Max. [3] PMV /f l) CO Range ax1O4
K*L/mol mol/L L/mol x 102 kg/mol kg/mol (kg/mol)2 mol/kg
ArgH(2 P04 )(-24.2 ± 3.4)[3] - 6ArgH(H2PO4) (25.6 ± 8.8)[3]2 6.3 0.2 15.50 + 1.44m 0.1885 -1.5303 -0.3143 0.2-0.4 2.4
ArgH(S4)1 2 (-43 ±0.5)[3] -ArgH(S4)12 (12.4 6.2)[3]2 5.4 0.5 13.50 + 0.36m 0.0279 -1.5809 -0.0454 0.7-1.3 1.9
ArgHCitate 112 (-18.5 +0.8)[3] +ArgH(Citrate)2(6.3 4.6)[3]2 3.3 0.5 16.73 + 0.53m 0.1146 -1.0850 -0.1123 0.6-1.2 4.0
ArgH(Acetate) N/A 0.0 0.5 16.30 + 0.40m N/A N/A N/A N/A N/A
ArgHF N/A 0.0 0.5 11.83 + 0.65m N/A N/A N/A N/A N/A
Argl~i (5.9±0.1)[3] - 0ArgHC (23.4 ± 4.8)[3]2 0.0 0.5 14.05 + 0.29m -0.0317 -0.3357 -0.0391 0.4-0.9 2.7
ArgHBr (5.95 ± .)[3]2 -7.7 0.5 14.54 + 0.08m -0.1532 0.0818 0.0093 0.4-0.9 1.4
ArgH (6.± 0.)[32 -22.6 0.5 15.89 + 0.57m -0.2996 0.2778 0.1215 0.4-0.9 2.4
ArgHSCN (5.9 ± 0.2)[3] -24.2 0.5 15.85 + 0.51m -0.3304 0.5404 0.1299 0.4-0.9 1.7
___________(11.2 ±4.3)[3] -
GdmCl (6.0 ±1)[3] -6.6 0.5 4.45 + 0.12m N/A N/A N/A N/A N/A
LtgHCl N/A N/A N/A N/A -0.0429 -0.3878 0.0084 0.1-1.6 30.0
aCgn solutions. for the F.3 (50 mg/mL) and Tm (1 mg/mL) data contained 20 mM sodium citrate pH 5 buffer.
PMV and Pitzer Ion Interaction Parameters data were for cosolute only solutions containing no buffering
component.
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